Unnamed: 0,title,date,stock,sentiment
904472.0,Nektar Therapeutics Highlights Data From Phase 1b Study Of NKTR-358 At European Congress Of Rheumatology,2020-06-04 17:02:00-04:00,NKTR,neutral
904473.0,Nektar Therapeutics Highlights Publication Of Results From Phase 1 Dose-Escalation Study For Bempegaldesleukin Plus Nivolumab In 'Cancer Discovery' Journal,2020-05-22 08:31:00-04:00,NKTR,negative
904474.0,"Oppenheimer Maintains Perform on Nektar Therapeutics, Raises Price Target to $25",2020-05-18 08:23:00-04:00,NKTR,neutral
904475.0,"HC Wainwright & Co. Reiterates Neutral on Nektar Therapeutics, Lowers Price Target to $26",2020-05-12 07:09:00-04:00,NKTR,negative
904476.0,"SVB Leerink Maintains Market Perform on Nektar Therapeutics, Raises Price Target to $18",2020-05-08 11:19:00-04:00,NKTR,neutral
904477.0,Nektar Therapeutics shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.,2020-05-08 10:21:00-04:00,NKTR,positive
904478.0,"Nektar Therapeutics Q1 EPS $(0.530) Beats $(0.710) Estimate, Sales $50.573M Beat $47.640M Estimate",2020-05-07 17:13:00-04:00,NKTR,neutral
904479.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,NKTR,negative
904480.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,NKTR,neutral
904481.0,"Benchmark Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target to $26",2020-04-22 08:13:00-04:00,NKTR,neutral
904482.0,Shares of several healthcare companies are trading higher amid optimistic coronavirus outlook following positive drug data from Gilead. This has raised hopes of a sooner return to spending and economic activity.,2020-04-17 10:04:00-04:00,NKTR,positive
904483.0,Nektar Therapeutics shares are trading higher after Goldman Sachs upgraded the company's stock from Sell to Neutral and raised its price target from $18 to $20.,2020-03-30 10:35:00-04:00,NKTR,positive
904484.0,"Benzinga's Top Upgrades, Downgrades For March 30, 2020",2020-03-30 09:35:00-04:00,NKTR,positive
904485.0,"Goldman Sachs Upgrades Nektar Therapeutics to Neutral, Raises Price Target to $20",2020-03-30 05:17:00-04:00,NKTR,neutral
904486.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus legislation has boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 09:22:00-04:00,NKTR,positive
904487.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,NKTR,neutral
904488.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 09:40:00-04:00,NKTR,negative
904489.0,"The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings",2020-03-13 07:52:00-04:00,NKTR,negative
904490.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,NKTR,negative
904491.0,Shares of several healthcare companies are trading higher as markets rebound following Monday's selloff. US President Trump on Monday indicated the US may implement payroll tax cuts and other measures to support the economy amid the coronavirus outbreak.,2020-03-10 07:54:00-04:00,NKTR,positive
904492.0,"JP Morgan Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $27",2020-03-09 08:21:00-04:00,NKTR,positive
904493.0,"Benzinga's Top Upgrades, Downgrades For March 4, 2020",2020-03-04 10:08:00-05:00,NKTR,positive
904494.0,"Barclays Initiates Coverage On Nektar Therapeutics with Overweight Rating, Announces $30 Price Target",2020-03-04 05:36:00-05:00,NKTR,negative
904495.0,Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.,2020-02-28 09:06:00-05:00,NKTR,negative
904496.0,"Nektar Therapeutics Q4 EPS $(0.64) Beats $(0.68) Estimate, Sales $33.9M Beat $26.93M Estimate",2020-02-27 16:17:00-05:00,NKTR,neutral
904497.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,NKTR,positive
904498.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,NKTR,negative
904499.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,NKTR,neutral
904500.0,Shares of several healthcare companies are trading higher in sympathy with the overall market after China reported the lowest number of new coronavirus cases since late January.,2020-02-12 11:05:00-05:00,NKTR,positive
904501.0,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.,2020-02-05 09:47:00-05:00,NKTR,positive
904502.0,85 Biggest Movers From Yesterday,2020-02-04 04:56:00-05:00,NKTR,neutral
904503.0,61 Stocks Moving In Monday's Mid-Day Session,2020-02-03 12:25:00-05:00,NKTR,neutral
904504.0,"Benzinga's Top Upgrades, Downgrades For February 3, 2020",2020-02-03 09:55:00-05:00,NKTR,positive
904505.0,Nektar Therapeutics shares are trading higher after Mizuho upgraded the stock from Neutral to Buy and raised the price target from $21 to $35 per share.,2020-02-03 08:28:00-05:00,NKTR,positive
904506.0,"Mizuho Upgrades Nektar Therapeutics to Buy, Raises Price Target to $35",2020-02-03 05:34:00-05:00,NKTR,neutral
904507.0,"Nektar Therapeutics shares are trading lower in sympathy with the overall market as concerns about the Wuhan coronavirus continue to grow, prompting travel bans in multiple Chinese cities.",2020-01-27 13:47:00-05:00,NKTR,positive
904508.0,26 Biotechnology Stocks Moving In Wednesday's After-Market Session,2020-01-22 23:28:00-05:00,NKTR,neutral
904509.0,36 Healthcare Stocks Moving In Wednesday's After-Market Session,2020-01-22 23:23:00-05:00,NKTR,neutral
904510.0,75 Biggest Movers From Yesterday,2020-01-16 04:37:00-05:00,NKTR,neutral
904511.0,Mid-Afternoon Market Update: OrganiGram Rises Following Q1 Results; Nektar Therapeutics Shares Plummet,2020-01-15 14:10:00-05:00,NKTR,positive
904512.0,Mid-Day Market Update: Concrete Pumping Falls On Weak Q4 Results; Fluent Shares Jump,2020-01-15 12:19:00-05:00,NKTR,negative
904513.0,36 Stocks Moving In Wednesday's Mid-Day Session,2020-01-15 12:07:00-05:00,NKTR,neutral
904514.0,"Benzinga Pro's Top 5 Stocks To Watch For Wed., Jan. 15, 2020: GS, RSX, NKTR, NVAX, ACB",2020-01-15 09:17:00-05:00,NKTR,positive
904515.0,Nektar Slumps As FDA Panel Gives Thumbs Down To Opioid Pain Drug; Program Shelved,2020-01-15 09:07:00-05:00,NKTR,negative
904516.0,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",2020-01-15 08:22:00-05:00,NKTR,negative
904517.0,34 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-15 08:10:00-05:00,NKTR,neutral
904518.0,21 Stocks Moving in Wednesday's Pre-Market Session,2020-01-15 07:43:00-05:00,NKTR,neutral
904519.0,Nektar Therapeutics shares are trading lower after the FDA AdCom panel voted unanimously against approval of the company's Oxycodegol painkiller.,2020-01-15 06:17:00-05:00,NKTR,positive
904520.0,Hearing FDA AdCom Panel Has Unanimously Voted Against Approval Of Nektar's Opioid Painkiller,2020-01-14 16:36:00-05:00,NKTR,positive
904521.0,Nektar Therapeutics shares are trading lower as the FDA's AdCom panel meeting on the company's Oxycodegol is underway. Unconfirmed rumors suggest data obtained from a study is not substantial enough to support proposed use.,2020-01-14 16:16:00-05:00,NKTR,positive
904522.0,Hearing Nektar After-Hours Downside Attributed To Comments From AdCom Panel On Oxycodegol Suggested Data Obtained From 1 Study Not Substantial Enough To Support Proposed Use,2020-01-14 16:16:00-05:00,NKTR,neutral
904523.0,Nektar Therapeutics Shares Down 20% On Heavy After-Hours Volume; FDA AdCom Panel Meeting On Co.'s Oxycodegol Currently Underway,2020-01-14 16:14:00-05:00,NKTR,positive
904524.0,"The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug",2020-01-14 07:55:00-05:00,NKTR,positive
904525.0,55 Biggest Movers From Friday,2020-01-13 05:17:00-05:00,NKTR,neutral
904526.0,"The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO",2020-01-12 17:05:00-05:00,NKTR,negative
904527.0,40 Stocks Moving In Friday's Mid-Day Session,2020-01-10 12:29:00-05:00,NKTR,neutral
904528.0,Nektar Therapeutics shares are trading higher after the company and Bristol-Myers agreed to a new joint development plan to advance bempeg plus nivolumab into multiple new registrational trials.,2020-01-10 09:59:00-05:00,NKTR,positive
904529.0,"UPDATE: Nektar, Bristol Amendment Includes ' new joint development plan under which Nektar and Bristol-Myers Squibb will expand the active clinical development program for bempeg plus nivolumab from three ongoing registrational trials'",2020-01-10 07:00:00-05:00,NKTR,positive
904530.0,"Nektar Therapeutics, Bristol-Myers Amend Strategic Collaboration For Bempegaldesleukin Plus Opdivo",2020-01-10 06:59:00-05:00,NKTR,neutral
904531.0,20 Stocks Moving in Thursday's Pre-Market Session,2020-01-09 06:57:00-05:00,NKTR,neutral
904532.0,Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates,2020-01-01 18:00:00-05:00,NKTR,neutral
904533.0,10 Stocks That Could Be Tax-Loss Buying Opportunities,2019-12-19 12:21:00-05:00,NKTR,positive
904534.0,80 Biggest Movers From Yesterday,2019-12-10 05:27:00-05:00,NKTR,neutral
904535.0,"Nektar Therapeutics shares are trading higher potentially after the company presented positive data for Abstract 2866 on Sunday, and in anticipation of the company presenting new preclinical data today at the ASH 2019 meeting.",2019-12-09 10:51:00-05:00,NKTR,positive
904536.0,Nektar Therapeutics shares are trading higher. Not seeing any news to justify the price action.,2019-12-09 09:52:00-05:00,NKTR,positive
904537.0,Nektar Therapeutics shares are trading higher in sympathy with the overall market amid a rally in US equities following strong November jobs data.,2019-12-06 14:18:00-05:00,NKTR,positive
904538.0,Nektar Therapeutics shares ar trading higher as the company presents at the Jefferies 2019 London Healthcare Conference.,2019-11-20 11:37:00-05:00,NKTR,positive
904539.0,72 Biggest Movers From Yesterday,2019-11-19 04:39:00-05:00,NKTR,neutral
904540.0,44 Stocks Moving In Monday's Mid-Day Session,2019-11-18 12:32:00-05:00,NKTR,neutral
904541.0,Nektar Therapeutics shares are trading lower. Not seeing any news to justify the price action.,2019-11-18 11:38:00-05:00,NKTR,neutral
904542.0,"JP Morgan Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $28",2019-11-13 08:53:00-05:00,NKTR,positive
904543.0,"Canaccord Genuity Maintains Buy on Nektar Therapeutics, Raises Price Target to $24",2019-11-12 08:12:00-05:00,NKTR,neutral
904544.0,UPDATE: H.C. Wainwright On Nektar Therapeutics Notes 'reasons to be cautious on this dataset include:',2019-11-11 11:56:00-05:00,NKTR,negative
904545.0,"UPDATE: H.C. Wainwright Maintains Neutral On Nektar Therapeutics, Raises Target To $32 As Firm Notes 'Upward Bias Exiting SITC'; 'Durability in frontline melanoma is reassuring, but we remain wary'",2019-11-11 11:56:00-05:00,NKTR,positive
904546.0,"H.C. Wainwright Earlier Maintained Neutral on Nektar Therapeutics, Raised Price Target to $32",2019-11-11 11:48:00-05:00,NKTR,neutral
904547.0,Nektar Therapeutics shares are trading higher after the company presented data from its first-in-human phase 1 trial of its NKTR-358 Novel T regulatory cell stimulator.,2019-11-11 08:38:00-05:00,NKTR,positive
904548.0,20 Stocks Moving in Monday's Pre-Market Session,2019-11-11 07:40:00-05:00,NKTR,neutral
904549.0,"Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at ACR 2019",2019-11-10 19:38:00-05:00,NKTR,positive
904550.0,Nektar Therapeutics shares are trading higher. Not seeing any news to justufy the price action.,2019-11-08 11:55:00-05:00,NKTR,positive
904551.0,These Are The Stocks Being Traded By Some Of The Top Traders On Webull,2019-11-08 11:44:00-05:00,NKTR,positive
904552.0,UPDATE: Piper Jaffray On Nektar Also Notes 'We look forward to the melanoma/PIVOT-02 cohort update at SITC this weekend and are encouraged to see more of the pipeline advance into clinical development (255/IL-15 and 358/T-reg)',2019-11-07 13:34:00-05:00,NKTR,positive
904553.0,"UPDATE: Piper Jaffray Maintains Overweight On Nektar, Lowers Tgt To $35 After Co. 'updated the timelines for topline readouts', Which Are Delayed Approx, 1 Year, 'For 3 of 6 planned registrational trials (1L melanoma, 1L bladder, and 1L RCC)' With BMY",2019-11-07 13:31:00-05:00,NKTR,negative
904554.0,Nekar Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.,2019-11-07 09:07:00-05:00,NKTR,positive
904555.0,10 Biggest Price Target Changes For Thursday,2019-11-07 08:26:00-05:00,NKTR,neutral
904556.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,NKTR,negative
904557.0,"Piper Jaffray Maintains Overweight on Nektar Therapeutics, Lowers Price Target to $35",2019-11-07 07:05:00-05:00,NKTR,negative
904558.0,"Nektar Therapeutics Q3 EPS $(0.56) Beats $(0.73) Estimate, Sales $29.218M Beat $26.4M Estimate",2019-11-06 17:10:00-05:00,NKTR,neutral
904559.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,NKTR,positive
904560.0,"The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight",2019-11-03 10:51:00-05:00,NKTR,neutral
904561.0,Nektar Therapeutics shares are trading higher on seemingly no company-specific news.,2019-11-01 11:51:00-04:00,NKTR,neutral
904562.0,Nektar Therapeutics shares are trading higher in sympathy with the overall market from progression in U.S.-China trade talks and positive sentiment from strong earnings reports.,2019-10-28 12:33:00-04:00,NKTR,positive
904563.0,"Oppenheimer Initiates Coverage On Nektar Therapeutics with Perform Rating, Announces $18 Price Target",2019-10-24 06:59:00-04:00,NKTR,neutral
904564.0,16 Stocks With The Highest Long-Term Sales Growth Rate,2019-10-23 15:26:00-04:00,NKTR,positive
904565.0,15 Stocks Projected To Have The Biggest 5-Year EPS Declines,2019-10-22 17:00:00-04:00,NKTR,neutral
904566.0,"Nektar Therapeutics Initiates First-In-Human Phase 1 Clinical Study Of NKTR-255, An IL-15 Agonist, In Adults With Relapsed Or Refractory Non-Hodgkin Lymphoma Or Multiple Myeloma",2019-10-16 09:02:00-04:00,NKTR,neutral
904567.0,63 Biggest Movers From Yesterday,2019-10-16 04:04:00-04:00,NKTR,neutral
904568.0,40 Stocks Moving In Tuesday's Mid-Day Session,2019-10-15 12:48:00-04:00,NKTR,neutral
904569.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-15 11:05:00-04:00,NKTR,negative
904570.0,Nektar Therapeutics shares are trading higher with the overall market. Not seeing any news to justify price action.,2019-10-15 10:47:00-04:00,NKTR,positive
904571.0,"The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings",2019-10-15 07:50:00-04:00,NKTR,positive
904572.0,Nektar Therapeutics shares are trading lower despite no company-specific news. The stock broke below the $16.25 support level and continued to trade lower.,2019-10-14 14:18:00-04:00,NKTR,negative
904573.0,Shares of several healthcare companies are trading higher after President Trump made positive remarks on the U.S.-China trade talks as traders grew more optimistic over the possibility of a limited trade deal. Trump is scheduled to meet with Chinese Vice Premier Liu He at the White House today.,2019-10-11 11:19:00-04:00,NKTR,positive
904574.0,Stocks That Hit 52-Week Lows On Thursday,2019-10-10 11:08:00-04:00,NKTR,negative
904575.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-09 12:55:00-04:00,NKTR,negative
904576.0,"The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug",2019-10-09 07:58:00-04:00,NKTR,negative
904577.0,42 Biggest Movers From Yesterday,2019-10-09 05:05:00-04:00,NKTR,neutral
904578.0,Nektar Hit With Double Downgrade From Goldman: 'Significant Challenges In Rebuilding Confidence',2019-10-08 14:00:00-04:00,NKTR,positive
904579.0,30 Stocks Moving In Tuesday's Mid-Day Session,2019-10-08 12:30:00-04:00,NKTR,neutral
904580.0,"UPDATE: Goldman Downgrades Nektar Therapeutics To Sell, Lowers Target To $16 As Believes 'near-term catalysts are unlikely to re-rate the stock in the face of quality issues and a narrower focus for bempegaldesleukin'",2019-10-08 11:03:00-04:00,NKTR,negative
904581.0,Shares of several healthcare companies are trading lower with the broader market after the US expanded its trade blacklist to include China's top AI firms. The US also will increase its tariffs on $250 billion worth of goods from 25% to 30% on Oct 15.,2019-10-08 10:36:00-04:00,NKTR,positive
904582.0,"Benzinga's Top Upgrades, Downgrades For October 8, 2019",2019-10-08 09:37:00-04:00,NKTR,positive
904583.0,10 Biggest Price Target Changes For Tuesday,2019-10-08 08:38:00-04:00,NKTR,neutral
904584.0,9 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-10-08 08:10:00-04:00,NKTR,neutral
904585.0,21 Stocks Moving in Tuesday's Pre-Market Session,2019-10-08 07:52:00-04:00,NKTR,neutral
904586.0,Nektar Therapeutics shares are trading lower after Goldman Sachs downgraded the company's stock from Buy to Sell and lowered the price target from $54 to $16.,2019-10-08 07:18:00-04:00,NKTR,negative
904587.0,"Goldman Sachs Downgrades Nektar Therapeutics to Sell, Lowers Price Target to $16",2019-10-08 06:57:00-04:00,NKTR,negative
904588.0,Nektar Therapeutics Announces Initiation Of Two Clinical Studies Of Novel T Regulatory Cell Stimulator NKTR-358 In Patients With Psoriasis And Atopic Dermatitis,2019-10-07 09:09:00-04:00,NKTR,positive
904589.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week.,2019-10-02 10:33:00-04:00,NKTR,negative
904590.0,Las Vegas Sands Set To Join S&P 500; Nektar Therapeutics To Join S&P Midcap 400,2019-09-26 17:19:00-04:00,NKTR,positive
904591.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,NKTR,neutral
904592.0,Nektar Therapeutics shares are trading lower after the company presented data from its PIVOT-02 study of bempegaldesleukin in triple-negative breast cancer patients,2019-09-26 09:49:00-04:00,NKTR,negative
904593.0,"The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J",2019-09-26 07:54:00-04:00,NKTR,positive
904594.0,Nektar Therapeutics Highlights Presentation Of Data From PIVOT-02 Study Of NKTR-214 With Nivolumab In Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference,2019-09-26 07:15:00-04:00,NKTR,negative
904595.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,NKTR,negative
904596.0,Nektar Therapeutics Announces Abstract Accepted For Presentation At The 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference,2019-09-23 17:00:00-04:00,NKTR,negative
904597.0,"Nektar Therapeutics shares trading higher for the fifth out of six days following news on Tuesday of last week the company's Chief Scientific Officer purchased 15,000 shares. The stock held above a $20 technical level today.",2019-09-16 13:47:00-04:00,NKTR,positive
904598.0,"Nektar Therapeutics Shares Spike Above $20 Resistance Level, Now Up 2% For Session",2019-09-11 11:05:00-04:00,NKTR,positive
904599.0,80 Biggest Movers From Yesterday,2019-09-11 05:11:00-04:00,NKTR,neutral
904600.0,"Nektar Therapeutics shares are trading higher in sympathy with the strength of the biotechnology sector. The company's Chief Scientific Officer, Stephen Doberstein, also bought 15,000 shares of the company's stock.",2019-09-10 13:49:00-04:00,NKTR,positive
904601.0,50 Stocks Moving In Tuesday's Mid-Day Session,2019-09-10 12:19:00-04:00,NKTR,neutral
904602.0,"The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings",2019-08-29 07:38:00-04:00,NKTR,negative
904603.0,The Week Ahead In Biotech: A Quiet One Ahead Of Labor Day Weekend,2019-08-25 15:06:00-04:00,NKTR,neutral
904604.0,Stocks That Hit 52-Week Lows On Wednesday,2019-08-21 10:46:00-04:00,NKTR,negative
904605.0,"The Daily Biotech Pulse: Ra Pharma Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform",2019-08-21 07:40:00-04:00,NKTR,neutral
904606.0,76 Biggest Movers From Yesterday,2019-08-13 04:57:00-04:00,NKTR,neutral
904607.0,Shares of several healthcare companies are trading lower in sympathy with the overall market as the Treasury yield continues to decline along with ongoing trade tensions with China.,2019-08-12 15:33:00-04:00,NKTR,positive
904608.0,54 Stocks Moving In Monday's Mid-Day Session,2019-08-12 12:20:00-04:00,NKTR,neutral
904609.0,90 Biggest Movers From Friday,2019-08-12 05:49:00-04:00,NKTR,neutral
904610.0,75 Stocks Moving In Friday's Mid-Day Session,2019-08-09 14:06:00-04:00,NKTR,neutral
904611.0,Large Option Trader Buying Nektar Calls Following Stock Crash,2019-08-09 14:03:00-04:00,NKTR,negative
904612.0,"A Look At Benzinga Pro's Most-Searched Tickers For August 9, 2019",2019-08-09 12:58:00-04:00,NKTR,neutral
904613.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Friday., August 09, 2019",2019-08-09 10:11:00-04:00,NKTR,positive
904614.0,"Nektar Therapeutics Tumbles To 2-Year Low On Q2 Revenue Miss, Manufacturing Issues With Cancer Drug",2019-08-09 10:08:00-04:00,NKTR,negative
904615.0,"Benzinga's Top Upgrades, Downgrades For August 9, 2019",2019-08-09 10:06:00-04:00,NKTR,positive
904616.0,What Caused The Opening Gap In Nektar?,2019-08-09 10:03:00-04:00,NKTR,neutral
904617.0,"BMO Capital Maintains Outperform on Nektar Therapeutics, Lowers Price Target to $41",2019-08-09 09:40:00-04:00,NKTR,negative
904618.0,31 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-09 09:00:00-04:00,NKTR,neutral
904619.0,10 Biggest Price Target Changes For Friday,2019-08-09 08:57:00-04:00,NKTR,neutral
904620.0,52 Stocks Moving In Friday's Pre-Market Session,2019-08-09 08:30:00-04:00,NKTR,neutral
904621.0,"Mizuho Downgrades Nektar Therapeutics to Neutral, Lowers Price Target to $21",2019-08-09 08:02:00-04:00,NKTR,negative
904622.0,Jefferies Downgrades Nektar Therapeutics to Hold,2019-08-09 08:01:00-04:00,NKTR,neutral
904623.0,Nektar Therapeutics shares are trading lower after the company reported worse-than-expected Q2 sales results. JP Morgan also downgraded the company's stock from Overweight to Neutral.,2019-08-09 07:30:00-04:00,NKTR,neutral
904624.0,"The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2",2019-08-09 07:19:00-04:00,NKTR,negative
904625.0,JP Morgan Downgrades Nektar Therapeutics to Neutral,2019-08-09 06:55:00-04:00,NKTR,positive
904626.0,50 Healthcare Stocks Moving In Thursday's After-Market Session,2019-08-08 21:56:00-04:00,NKTR,neutral
904627.0,Nektar Therapeutics Shares Fall 33% Following Q2 Earnings Report,2019-08-08 18:21:00-04:00,NKTR,positive
904628.0,"Nektar Shares Resume Trade, Down 20+%",2019-08-08 18:01:00-04:00,NKTR,positive
904629.0,"Nektar Therapeutics Says it Has Experienced Delays With its Bempegaldesleukin Program, Says Will Discuss on the Quarterly Conference Call at 5pm ET",2019-08-08 16:20:00-04:00,NKTR,neutral
904630.0,"Nektar Therapeutics Q2 EPS $(0.63) Beats $(0.8) Estimate, Sales $23.3M Miss $26.65M Estimate",2019-08-08 16:17:00-04:00,NKTR,negative
904631.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,NKTR,neutral
904632.0,Stocks That Fell Through 52-Week Lows Wednesday,2019-08-07 14:22:00-04:00,NKTR,negative
904633.0,"The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts",2019-08-03 10:18:00-04:00,NKTR,neutral
904634.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-01 09:38:00-04:00,NKTR,neutral
904635.0,Nektar Therapeutics And Bristol-Myers Squibb Announce FDA Breakthrough Therapy Designation For NKTR-214 In Combination With Opdivo For The Treatment Of Patients With Untreated Advanced Melanoma,2019-08-01 07:46:00-04:00,NKTR,positive
904636.0,Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates,2019-07-31 17:15:00-04:00,NKTR,neutral
904637.0,Nektar Therapeutics Option Alert: Aug 16 $32 Calls Sweep (2) near the Ask: 800 @ $0.526 vs 447 OI; Earnings 8/7 After Close [est] Ref=$28.6699,2019-07-30 11:48:00-04:00,NKTR,positive
904638.0,New 52-Week Lows for Tuesday Morning,2019-07-30 11:07:00-04:00,NKTR,negative
904639.0,Nektar Therapeutics shares are trading lower on seemingly no company-specific news.,2019-07-29 13:35:00-04:00,NKTR,negative
904640.0,Nektar Therapeutics Option Alert: Jan 17 $40 Calls at the Ask: 5000 @ $2.3 vs 436 OI; Earnings 8/7 After Close [est] Ref=$30.0891,2019-07-26 09:55:00-04:00,NKTR,positive
904641.0,Nektar Therapeutics shares are trading lower after the company's 8-K showed that the FDA would postpone the product specific advisory committee meeting for Opioid Analgesics. The FDA said the reason for postponement was not unique to Nektar.,2019-07-25 08:46:00-04:00,NKTR,negative
904642.0,UPDATE: Nektar Notes FDA Letter States Reason For Postponement Not Unique To Nektar; FDA Will Continue To Review NDA For NKTR-181 According To Existing PDUFA Timeline,2019-07-25 08:09:00-04:00,NKTR,neutral
904643.0,Nektar Therapeutics 8-K Shows Co. Received General Advice Letter From FDA For New Drug Application On NKTR-181: FDA Will Postpone Product-Specific Advisory Committee Meetings For Opiod Analgesics,2019-07-25 08:08:00-04:00,NKTR,negative
904644.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,NKTR,negative
904645.0,"The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes",2019-06-13 07:44:00-04:00,NKTR,negative
904646.0,Nektar Therapeutics Reports Results Of Phase 1a Study Of NKTR-358 As T Regulatory Cell Stimulator To Be Presented At EULAR,2019-06-13 06:52:00-04:00,NKTR,neutral
904647.0,"BioXcel Pharmaceuticals CEO On Drug Pipeline, How AI Is Changing Sector",2019-06-09 16:09:00-04:00,NKTR,neutral
904648.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts",2019-06-08 16:09:00-04:00,NKTR,neutral
904649.0,66 Biggest Movers From Yesterday,2019-06-04 05:19:00-04:00,NKTR,neutral
904650.0,51 Stocks Moving In Monday's Mid-Day Session,2019-06-03 12:46:00-04:00,NKTR,neutral
904651.0,"Shares of several biotechs are trading higher in sympathy with Amgen after the company presented the first clinical data evaluating a KRASG12C inhibitor, AMG 510, at ASCO 2019.",2019-06-03 09:32:00-04:00,NKTR,positive
904652.0,30 Stocks Moving In Monday's Pre-Market Session,2019-06-03 08:12:00-04:00,NKTR,neutral
904653.0,Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at #ASCO19; 42% of Patients Achieved a Maximum Reduction of 100% in Target Lesions,2019-06-01 14:22:00-04:00,NKTR,neutral
904654.0,The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace,2019-06-01 11:37:00-04:00,NKTR,neutral
904655.0,"Trovagene Reports Research Collab With Nektar Therapeutics To Evaluate Efficacy Of Combo Of Onvansertib, ONZEALD In Models Of Colorectal Cancer",2019-05-23 08:06:00-04:00,NKTR,negative
904656.0,Nektar Therapeutics Highlights Launch Of Inheris Biopharma,2019-05-23 08:04:00-04:00,NKTR,neutral
904657.0,"Jim Cramer Weighs In On Nektar, L Brands And More",2019-05-22 07:29:00-04:00,NKTR,neutral
904658.0,5 ASCO Abstracts That Moved Stocks,2019-05-16 14:50:00-04:00,NKTR,neutral
904659.0,Nektar Therapeutics Highlights 5 Accepted Abstracts At ASCO,2019-05-15 17:04:00-04:00,NKTR,positive
904660.0,"Shares of several healthcare companies are trading lower amid continued trade dispute between the US and China. Also, the United States filed a lawsuit against drug manufacturers alleging price fixing.",2019-05-13 10:35:00-04:00,NKTR,negative
904661.0,"Nektar Therapeutics Q1 EPS $(0.68) Down From $(0.6) YoY, Sales $28.222M Down From $38.018M YoY",2019-05-08 17:42:00-04:00,NKTR,neutral
904662.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,NKTR,negative
904663.0,Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.,2019-04-30 12:16:00-04:00,NKTR,negative
904664.0,"Jim Cramer Weighs In On Oracle, Bluebird Bio And More",2019-04-16 07:51:00-04:00,NKTR,neutral
904665.0,Nektar Therapeutics Highlights Presentation Of Preclinical Data On Its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019,2019-04-02 15:05:00-04:00,NKTR,negative
904666.0,"The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial",2019-04-02 07:30:00-04:00,NKTR,neutral
904667.0,"Nektar Therapeutics, Vaccibody Highlight Presentation Of Preclinical Data For VB10.NEO At AACR Meeting",2019-04-01 16:20:00-04:00,NKTR,positive
904668.0,"BioXcel Therapeutics Announces Addition Of Merck KGaA, Darmstadt, Germany, And Pfizer To Clinical Collaboration With Nektar For Development Of Triple-combination Therapy In Pancreatic Cancer",2019-03-04 08:13:00-05:00,NKTR,negative
904669.0,BioXcel Therapeutics Announces Merck and Pfizer Join its Clinical Collaboration with Nektar Therapeutics to Evaluate a Triple Therapy for Pancreatic Cancer,2019-03-04 08:07:00-05:00,NKTR,negative
904670.0,81 Biggest Movers From Friday,2019-03-04 05:39:00-05:00,NKTR,neutral
904671.0,"Nektar Therapeutics Highlights Presentation Of Preliminary Immune Activation, Safety And Clinical Activity Data From The Ongoing Dose-Escalation Stage Of REVEAL Study At 2019 ASCO-SITC Meeting",2019-03-01 16:42:00-05:00,NKTR,positive
904672.0,64 Stocks Moving In Friday's Mid-Day Session,2019-03-01 13:18:00-05:00,NKTR,neutral
904673.0,"Nektar Therapeutics Q4 EPS $(0.57) Misses $(0.54) Estimate, Sales $39.8M Miss $45.92M Estimate",2019-02-28 16:12:00-05:00,NKTR,negative
904674.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,NKTR,positive
904675.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,NKTR,neutral
904676.0,"BMO Capital Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces $75 Price Target",2019-02-22 07:18:00-05:00,NKTR,neutral
904677.0,UPDATE: Nektar Says 'translational research demonstrated that in patients with the highest unmet medical need...treatment with the combo resulted in 70% of patients converting to PD-L1 positive expressors',2019-02-15 15:19:00-05:00,NKTR,positive
904678.0,UPDATE: Nektar Says Stage IV With Median Age 70 Cohort 'was generally well tolerated with no Grade 4 or 5 adverse events reported',2019-02-15 15:19:00-05:00,NKTR,negative
904679.0,UPDATE: Nektar Says 'responses were observed regardless of baseline PD-L1 expression and no relapses occurred',2019-02-15 15:18:00-05:00,NKTR,negative
904680.0,"UPDATE: Nektar Says Prelim. Results From PIVOT-02 Study Of NKTR-214 Combo Shares In Poster Presentation Fri., Showed 'important response rates, including complete responses, in patients who were cisplatin-ineligible or refused standard of care'",2019-02-15 15:18:00-05:00,NKTR,positive
904681.0,"Nektar Therapeutics Issues Press Release Highlighting Presentation Of New Data For NKTR-214 In Combo With Nivolumab For Advanced, Metastatic Urothelial Carcinoma At ASCO GU",2019-02-15 15:17:00-05:00,NKTR,positive
904682.0,"The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal",2019-02-15 07:39:00-05:00,NKTR,positive
904683.0,58 Biggest Movers From Yesterday,2019-02-13 04:43:00-05:00,NKTR,neutral
904684.0,44 Stocks Moving In Tuesday's Mid-Day Session,2019-02-12 12:18:00-05:00,NKTR,neutral
904685.0,Nektar Therapeutics shares are trading lower after the company announced a 48% response rate for its urothelial cancer treatment versus 60% previously.,2019-02-12 08:51:00-05:00,NKTR,negative
904686.0,"The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares",2019-02-12 08:04:00-05:00,NKTR,negative
904687.0,Nektar Therapeutics Option Alert: Oct 18 $65 Calls at the Ask: 500 @ $3.351 vs 0 OI; Earnings 2/28 After Close [est] Ref=$42.625,2019-02-04 14:30:00-05:00,NKTR,positive
904688.0,"Notable Biotech Source, Twitter Account Andy Biotech, Tweets 'Cytokines continue to be one of the hottest thing in #immunotherapy...and a new startup @neoleukin -> watch out $NKTR $THOR'",2019-01-10 09:07:00-05:00,NKTR,neutral
904689.0,Nektar Therapeutics shares are trading higher after the company outlined a research collaboration with Gilead at JP Morgan's healthcare conference.,2019-01-08 15:02:00-05:00,NKTR,positive
904690.0,"UPDATE: Nektar Says Gilead Will Be Responsible For Preclinical Studies, Costs",2019-01-08 11:40:00-05:00,NKTR,positive
904691.0,UPDATE: Nektar Research Collab With Gilead Will Be For Exploration Of Combo Between Co.'s NKTR-225 And Gilead's Effector-Memory T Cells With Antiretroviral Therapies,2019-01-08 11:40:00-05:00,NKTR,positive
904692.0,"Nektar Therapeutics 8-K Shows Pres, CEO Will Make Presentation At JP Morgan Healthcare Conference; Will Outline Research Collab With Gilead; Will Show $1.92B In Cash, Equivalents as Of Dec. 31, 2018",2019-01-08 11:37:00-05:00,NKTR,positive
904693.0,6 Valuable Pipeline Drugs With Upcoming Catalysts,2018-12-26 14:22:00-05:00,NKTR,positive
904694.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,NKTR,neutral
904695.0,Nektar Therapeutics shares are trading up 3% after Goldman Sachs initiated with a Buy and announced a $62 price target.,2018-12-13 11:32:00-05:00,NKTR,positive
904696.0,"Goldman Sachs Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces $62 Price Target",2018-12-13 09:28:00-05:00,NKTR,neutral
904697.0,Nektar Therapeutics Option Alert: Jan 18 $40 Calls at the Ask: 1839 @ $2.8 vs 1055 OI; Ref=$37.19,2018-11-21 11:35:00-05:00,NKTR,positive
904698.0,"Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $86",2018-11-13 08:41:00-05:00,NKTR,negative
904699.0,"The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall",2018-11-09 07:32:00-05:00,NKTR,neutral
904700.0,"Jefferies Maintains Buy on Nektar Therapeutics, Lowers Price Target to $73",2018-11-08 11:59:00-05:00,NKTR,negative
904701.0,"Nektar Therapeutics Q3 EPS $(0.56) Beats $(0.63) Estimate, Sales $27.762M Beat $26.08M Estimate",2018-11-07 17:29:00-05:00,NKTR,neutral
904702.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,NKTR,negative
904703.0,Nektar Therapeutics Q3 Earnings Outlook,2018-11-07 07:18:00-05:00,NKTR,neutral
904704.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,NKTR,neutral
904705.0,Nektar Therapeutics Option Alert: Nov 16 $40 Calls Sweep (38) above Ask!: 674 @ $3.898 vs 788 OI; Earnings 11/6 After Close [est] Ref=$38.45,2018-10-23 13:22:00-04:00,NKTR,positive
904706.0,58 Biggest Movers From Yesterday,2018-10-23 05:09:00-04:00,NKTR,neutral
904707.0,3 Screens That Hint At Which Stocks May Outperform In Q4,2018-10-05 11:57:00-04:00,NKTR,neutral
904708.0,"Jim Cramer Gives His Opinion On Anheuser-Busch, Nektar, Walker & Dunlop And More",2018-10-05 08:14:00-04:00,NKTR,neutral
904709.0,48 Biggest Movers From Yesterday,2018-10-02 04:51:00-04:00,NKTR,neutral
904710.0,38 Stocks Moving In Monday's Mid-Day Session,2018-10-01 12:18:00-04:00,NKTR,neutral
904711.0,Nektar Therapeutics shares are down 7.6% as traders circulate report from short seller Plainview; Report highlights value of stock at 'zero'.,2018-10-01 10:58:00-04:00,NKTR,positive
904712.0,"Traders Circulating Report From Short Seller Plainview On Nektar Therapeutics, Highlights Value Of Stock At 'Zero'",2018-10-01 09:34:00-04:00,NKTR,positive
904713.0,BioXcel Therapeutics Expands Immuno-Oncology Partnership with Nektar into Clinical Development in Pancreatic Cancer,2018-09-24 07:29:00-04:00,NKTR,negative
904714.0,"Nektar Therapeutics Q2 EPS $5.33 Beats $5.22 Estimate, Sales $1.088B Beat $1.03B Estimate",2018-08-08 16:13:00-04:00,NKTR,neutral
904715.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,NKTR,positive
904716.0,"Earnings Scheduled For August 8, 2018",2018-08-08 06:03:00-04:00,NKTR,neutral
904717.0,Nektar Therapeutics Reports New Drug Application For NKTR-181 Accepted For Review By FDA,2018-07-30 09:16:00-04:00,NKTR,positive
904718.0,IsoPlexis Reports Research Partnership with Nektar Therapeutics,2018-06-26 08:06:00-04:00,NKTR,neutral
904719.0,21 Stocks Moving In Tuesday's Pre-Market Session,2018-06-19 08:14:00-04:00,NKTR,neutral
904720.0,"Nektar Up 3% Since 10 a.m. Release On Presentation Of Preclinical Comments For NKTR-181 This Week; Mizuho Analyst, Asked If Release Could Have Moved Stock, Said 'NKTR-181 accounts for $2-3/share in my valuation, so I don't think it can move the stock'",2018-06-14 11:39:00-04:00,NKTR,neutral
904721.0,Nektar Therapeutics Option Alert: Jan 18 $60 Puts at the Bid: 600 @ $15.651 vs 393 OI; Earnings 8/7 After Close [est] Ref=$54.08,2018-06-14 10:17:00-04:00,NKTR,positive
904722.0,"Benzinga's Top Upgrades, Downgrades For June 11, 2018",2018-06-11 09:22:00-04:00,NKTR,positive
904723.0,"H.C. Wainwright Downgrades Nektar Therapeutics to Neutral, Announces $54 Price Target",2018-06-11 07:08:00-04:00,NKTR,neutral
904724.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs",2018-06-10 17:29:00-04:00,NKTR,neutral
904725.0,45 Biggest Movers From Yesterday,2018-06-08 04:07:00-04:00,NKTR,neutral
904726.0,"Nektar Therapeutics Shares Volatile Here; Co. Mulling Possible NKTR-181 Licensing To Commercial Partners, Also Considering Other Strategic Structural Alternatives",2018-06-06 15:15:00-04:00,NKTR,positive
904727.0,Nektar Therapeutics Option Alert: Jun 15 $60 Puts Sweep (2) near the Ask: 2825 @ $1.801 vs 4083 OI; Ref=$64.32,2018-06-06 12:04:00-04:00,NKTR,positive
904728.0,Nektar Therapeutics Option Alert: Nov 16 $45 Puts at the Bid: 2300 @ $5.8 vs 322 OI; Ref=$56.64,2018-06-05 13:08:00-04:00,NKTR,positive
904729.0,"Shares Of Nektar Spike To High Of $56.68, Now Up ~7.5% On The Day",2018-06-05 13:00:00-04:00,NKTR,positive
904730.0,Nektar Therapeutics Option Alert: Nov 16 $75 Puts at the Bid: 6312 @ $25.15 vs 6313 OI; Ref=$55.44,2018-06-05 12:55:00-04:00,NKTR,positive
904731.0,44 Biggest Movers From Yesterday,2018-06-05 05:27:00-04:00,NKTR,neutral
904732.0,"Benzinga Pro's Top 10 Most-Searched Tickers For The Evening Of Mon., Jun. 4",2018-06-04 16:44:00-04:00,NKTR,positive
904733.0,"Nektar Therapeutics Shares Down ~43.5% Ahead Of Close Following Prelim. Data From Co., Bristol-Myers Related To NKTR-214 In Combo With Opdivo",2018-06-04 15:49:00-04:00,NKTR,positive
904734.0,Mid-Afternoon Market Update: Dow Up 180 Points; Nektar Therapeutics Shares Plummet,2018-06-04 14:32:00-04:00,NKTR,positive
904735.0,5 Biotech Stocks Moving On ASCO Presentations,2018-06-04 13:18:00-04:00,NKTR,neutral
904736.0,35 Stocks Moving In Monday's Mid-Day Session,2018-06-04 12:32:00-04:00,NKTR,neutral
904737.0,Mid-Day Market Update: Crude Oil Down 1.5%; American Electric Technologies Shares Spike Higher,2018-06-04 12:07:00-04:00,NKTR,negative
904738.0,"Nektar Therapeutics Option Alert: Jan 18, 2019 $55 Puts at the Ask: 612 @ $13.6 vs 113 OI; Ref=$53.7",2018-06-04 11:03:00-04:00,NKTR,positive
904739.0,Mid-Morning Market Update: Markets Open Higher; Palo Alto Networks Beats Q3 Estimates,2018-06-04 10:13:00-04:00,NKTR,neutral
904740.0,28 Stocks Moving In Monday's Pre-Market Session,2018-06-04 08:11:00-04:00,NKTR,neutral
904741.0,40 Biggest Movers From Friday,2018-06-04 04:33:00-04:00,NKTR,neutral
904742.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,NKTR,negative
904743.0,"Nektar, ristol-Myers Squibb Announce Preliminary Data for NKTR-214 in Combination with Opdivo for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at #ASCO2018",2018-06-02 20:37:00-04:00,NKTR,neutral
904744.0,"Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time",2018-05-31 08:22:00-04:00,NKTR,positive
904745.0,Nektar Therapeutics Reports Submission Of NDA For NKTR-181 For Treatment Of Chronic Low Back Pain In Adults Patients New To Opioid Therapy,2018-05-31 08:16:00-04:00,NKTR,negative
904746.0,"Syndax Pharma, Nektar Therapeutics Report Non-Exclusive, Clinical Collab. To Evaluate Safety, Efficacy Of Nektar's NKTR-214 In Combo With Syndax's Entinostat In Patients With Metastatic Melanoma Previously Progressed On Treatment With Anti-PD-1 Agent",2018-05-30 16:09:00-04:00,NKTR,positive
904747.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2018-05-26 11:07:00-04:00,NKTR,neutral
904748.0,48 Biggest Movers From Yesterday,2018-05-18 04:54:00-04:00,NKTR,neutral
904749.0,32 Stocks Moving In Thursday's Mid-Day Session,2018-05-17 12:34:00-04:00,NKTR,neutral
904750.0,Nektar Therapeutics Late Wednesday Announced Six Abstracts Accepted for Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting,2018-05-17 08:44:00-04:00,NKTR,positive
904751.0,"Nektar Therapeutics Q1 EPS $(0.60) May Not Compare Tp $0.09 Estimate, Sales $38.02M Miss $165.34M Estimate",2018-05-10 16:17:00-04:00,NKTR,negative
904752.0,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",2018-05-10 09:44:00-04:00,NKTR,neutral
904753.0,Nektar Therapeutics Reports Initiation Of Phase 1b Study Of NKTR-358 For Patients With Systemic Lupus Erythematosus,2018-05-08 08:34:00-04:00,NKTR,neutral
904754.0,"Jim Cramer Advises His Viewers On Prestige Brands, CVS Health And More",2018-05-08 07:32:00-04:00,NKTR,neutral
904755.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,NKTR,neutral
904756.0,Nektar Reports New Clinical Collaboration With Takeda To Evaluate Co.'s NKTR-214 With Takeda's TAK-659 As Regimen For Multiple Cancer Settings,2018-04-24 08:34:00-04:00,NKTR,negative
904757.0,"Seaport Global Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces $120.00 Price Target",2018-04-20 09:46:00-04:00,NKTR,neutral
904758.0,38 Biggest Movers From Yesterday,2018-04-17 04:46:00-04:00,NKTR,neutral
904759.0,31 Stocks Moving In Monday's Mid-Day Session,2018-04-16 12:19:00-04:00,NKTR,neutral
904760.0,Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at #AACR18,2018-04-16 04:01:00-04:00,NKTR,neutral
904761.0,"PiperJaffray Reinstates Overweight on Nektar Therapeutics, Announces $125.00",2018-04-13 07:58:00-04:00,NKTR,negative
904762.0,Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors,2018-04-11 08:00:00-04:00,NKTR,positive
904763.0,40 Biggest Movers From Yesterday,2018-04-10 04:21:00-04:00,NKTR,neutral
904764.0,"Biotech Stocks Underperforming The Market, With The SPDR Biotech ETF (XBI) Down 3.2%, Stocks Down Hardest Include: ALNA -20.3%, JNCE -9%, NKTR -10.9%, MRTX -10.3%, ARMO -8.7%",2018-04-06 14:52:00-04:00,NKTR,neutral
904765.0,"Benzinga's Top Analyst Calls From April 6, 2018",2018-04-06 14:39:00-04:00,NKTR,positive
904766.0,"Mizuho Out Positive On Nektar Therapeutics Says Incyte's epacadostat Phase 3 Failure Is A Positive For The Company, Believes This News Raises The Possibility Of A Takeout By BMS In The Coming Months",2018-04-06 13:07:00-04:00,NKTR,positive
904767.0,Hearing Mizuho Raised Nektar Price Target From $89 To $103,2018-04-06 13:03:00-04:00,NKTR,neutral
904768.0,24 Stocks Moving In Friday's Mid-Day Session,2018-04-06 12:26:00-04:00,NKTR,neutral
904769.0,'$NKTR is the new $INCY. Anyone worried about that now?' -Adam Feuerstein Tweet,2018-04-06 09:00:00-04:00,NKTR,negative
904770.0,"Nektar Therapeutics Announces Bristol-Myers' Collaboration Effective Today, Resulting In Nektar's Receipt Of $1B Upfront Cash Payment",2018-04-03 17:38:00-04:00,NKTR,positive
904771.0,"Benzinga's Top Upgrades, Downgrades For April 2, 2018",2018-04-02 09:12:00-04:00,NKTR,positive
904772.0,"H.C. Wainwright Assumes Nektar Therapeutics at Buy, Announces $125 Price Target",2018-04-02 07:06:00-04:00,NKTR,neutral
904773.0,The S&P 500's Biggest Gainers And Losers In A Turbulent First Quarter,2018-04-01 10:00:00-04:00,NKTR,negative
904774.0,An Eventful February Took Its Toll On TD Ameritrade's Investor Index,2018-03-06 16:17:00-05:00,NKTR,neutral
904775.0,42 Biggest Movers From Friday,2018-03-05 05:08:00-05:00,NKTR,neutral
904776.0,Mid-Afternoon Market Update: Nektar Therapeutics Gains After Q4 Results; Foot Locker Shares Plummet,2018-03-02 14:31:00-05:00,NKTR,positive
904777.0,Nektar Therapeutics Shares Up 23.2% After Co. Reported Late Thursday Q4 Earnings Beat,2018-03-02 13:19:00-05:00,NKTR,positive
904778.0,32 Stocks Moving In Friday's Mid-Day Session,2018-03-02 12:20:00-05:00,NKTR,neutral
904779.0,"Nektar Therapeutics Reports Q4 EPS $(0.21) vs $(0.35) Est., Sales $95.5M May Not Compare to $36.98M Est.",2018-03-01 16:13:00-05:00,NKTR,neutral
904780.0,Nektar Therapeutics Q4 Earnings Preview,2018-03-01 11:26:00-05:00,NKTR,neutral
904781.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-02-25 15:50:00-05:00,NKTR,neutral
904782.0,"Adam Feuerstein Tweet:For $BMY — Paying a ton for NKTR-214 doesn't exactly inspire confidence in Opdivo business, as is. What is lurking under the hood of the -227 study we haven't seen?",2018-02-14 07:08:00-05:00,NKTR,negative
904783.0,"Bristol-Myers Squibb, Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar's CD122-biased Agonist, NKTR-214; Nektar To Pay $1.85B Upfront Comprised Of $1B In Cash & Purchase Of 8.28M Shares At $102.60/Share",2018-02-14 07:00:00-05:00,NKTR,positive
904784.0,Nektar Therapeutics Shares Fall To Low Of $70.72/Share Down 9.3%,2018-02-07 13:16:00-05:00,NKTR,neutral
904785.0,"Shares of Alkermes Trade Higher Following Chatter That Nektar Therapeutics Has Takeover Interest from Larger Drug Makers, Alkermes' Products Have Similarities to Nektar",2018-02-02 15:30:00-05:00,NKTR,positive
904786.0,"Watching Shares of Nektar Therapetuics As Co. Said To Be Exploring A Sale, Unconfirmed",2018-02-02 13:57:00-05:00,NKTR,positive
904787.0,"Nektar Shares Continuing Higher Over $85 Resistance Level, Now Up 3.3% For Session To Over $86; Stock Up 48% Since Jan. 9; Saw Notable Option Activity On Jan. 10: Jan. $65, $70 Calls, Feb. $65 Calls",2018-02-01 10:53:00-05:00,NKTR,positive
904788.0,"Nektar Therapeutics Shares Up ~3% Over Last Few Mins, Bouncing Off $83 Level; Stock Up 2.1% For Session",2018-02-01 10:06:00-05:00,NKTR,positive
904789.0,Here's Why Nektar Stock Skyrocketed Almost 500% In A Year,2018-01-19 12:46:00-05:00,NKTR,neutral
904790.0,Nektar Option Alert: Feb 16 $65 Calls Sweep (16) at the Ask: 600 @ $7.201 vs 450 OI; Earnings 2/28 After Close [est] Ref=$67.7,2018-01-10 14:55:00-05:00,NKTR,positive
904791.0,Nektar Option Alert: Jan 19 $65 Calls Sweep (6) at the Bid: 500 @ $7.75 vs 5685 OI; Earnings 2/28 After Close [est] Ref=$73.05,2018-01-10 09:55:00-05:00,NKTR,positive
904792.0,40 Biggest Movers From Yesterday,2018-01-10 04:34:00-05:00,NKTR,neutral
904793.0,"STAT News' Adam F. Tweets: '$NKTR The irrational exuberance for NKTR-214 continues, I presume? #JPM18'",2018-01-09 15:18:00-05:00,NKTR,negative
904794.0,Mid-Afternoon Market Update: Pain Therapeutics Jumps On Clinical Study Data; Big 5 Sporting Goods Shares Plummet,2018-01-09 14:31:00-05:00,NKTR,negative
904795.0,Mid-Day Market Update: Dow Surges Over 100 Points; e.l.f. Beauty Shares Drop,2018-01-09 12:42:00-05:00,NKTR,positive
904796.0,Mid-Morning Market Update: Markets Mostly Higher; Acuity Brands Profit Misses Views,2018-01-09 10:46:00-05:00,NKTR,positive
904797.0,The Companies That Led 2017's Biotech Rally,2017-12-22 09:50:00-05:00,NKTR,neutral
904798.0,"Nektar Therapeutics 8-K Filing Shows Co. Received Formal Notice Of Termination From Bayer For Co-Development, License, Co-Promotion Deal",2017-12-15 07:37:00-05:00,NKTR,neutral
904799.0,"Piper Jaffray Healthcare Conference 2017 Begins Today, Presenters Include: Civitas Solutions, Insulet, ACADIA Healthcare, Nektar Therapeutics, Quidel, and Arrowhead Pharmaceuticals",2017-11-28 08:57:00-05:00,NKTR,positive
904800.0,25 Stocks Moving In Friday's Pre-Market Session,2017-11-24 08:05:00-05:00,NKTR,neutral
904801.0,A Peek Into The Markets: U.S. Stock Futures Rise On Black Friday,2017-11-24 06:47:00-05:00,NKTR,neutral
904802.0,"UPDATE: Nektar Says Co. Will Not Incur ~$25M-$30M In Commercial Manufacturing Scale-Up, Readiness Costs Over Next 12-18 Mos.",2017-11-24 06:26:00-05:00,NKTR,positive
904803.0,"UPDATE: Nektar Says Will Incur $3-$4M Of Wind-Down Costs Related To Conclusion Of Co.'s Activities, Commitments To CMOs",2017-11-24 06:25:00-05:00,NKTR,positive
904804.0,"UPDATE: Nektar Highlights Bayer Announced Phase 3 Amikacin Inhale Did Not Meet Primary Or Key Secondary Endpoints; Co. Does Not Expect Bayer To Move Forward With Program, Does Not Expect Any Further Performance Obligations",2017-11-24 06:24:00-05:00,NKTR,neutral
904805.0,Nektar Therapeutics 8-K Shows Co. Retained Rights Under '07 Deal With Bayer For Amikacin Inhale For Aerosolized Treatment Of Gram Negative Pneumonias,2017-11-24 06:23:00-05:00,NKTR,negative
904806.0,Bayer Announces Phase Iii Study With Amikacin Inhale In Intubated And Mechanically Ventilated Patients With Gram-Negative Pneumonia Does Not Meet Primary Endpoint Of Superiority,2017-11-24 04:39:00-05:00,NKTR,positive
904807.0,32 Stocks Moving In Wednesday's Pre-Market Session,2017-11-22 08:05:00-05:00,NKTR,neutral
904808.0,34 Biggest Movers From Yesterday,2017-11-14 05:52:00-05:00,NKTR,neutral
904809.0,28 Stocks Moving In Monday's Mid-Day Session,2017-11-13 12:47:00-05:00,NKTR,neutral
904810.0,Analyst: Nektar Has A Handful Of Milestones Ahead In 2018,2017-11-13 11:49:00-05:00,NKTR,neutral
904811.0,"Canaccord Genuity Maintains Buy on Nektar Therapeutics, Raises Price Target to $50.00",2017-11-13 11:14:00-05:00,NKTR,neutral
904812.0,Mid-Morning Market Update: Markets Edge Lower; Tyson Foods Tops Q4 Expectations,2017-11-13 10:14:00-05:00,NKTR,positive
904813.0,28 Stocks Moving In Monday's Pre-Market Session,2017-11-13 08:06:00-05:00,NKTR,neutral
904814.0,Nektar Therapeutics +20% Premarket $39; Co Announced Presentation of Encouraging Data from PIVOT-02 Phase 1/2 Study Showing Potential Benefits Presented at SITC 2017,2017-11-13 07:25:00-05:00,NKTR,positive
904815.0,"Nektar Therapeutics, Bristol-Myers Squibb Announce First Presentation of Data from PIVOT-02 Phase 1/2 Study Showing Potential Benefits Presented at SITC 2017",2017-11-12 07:30:00-05:00,NKTR,positive
904816.0,"Benzinga's Top Upgrades, Downgrades For November 9, 2017",2017-11-09 08:57:00-05:00,NKTR,positive
904817.0,"Canaccord Genuity Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces $35.00 Price Target",2017-11-09 08:37:00-05:00,NKTR,neutral
904818.0,57 Biggest Movers From Yesterday,2017-11-09 05:16:00-05:00,NKTR,neutral
904819.0,4 Q3 Earnings Winners Breaking Out,2017-11-08 12:56:00-05:00,NKTR,positive
904820.0,46 Stocks Moving In Wednesday's Mid-Day Session,2017-11-08 12:31:00-05:00,NKTR,neutral
904821.0,32 Stocks Moving In Wednesday's Pre-Market Session,2017-11-08 08:08:00-05:00,NKTR,neutral
904822.0,"Nektar Therapeutics Reports Q3 EPS $0.37 vs. $(0.32) In Same Qtr. Last Year, Sales $152.928M vs $36.336M YoY",2017-11-07 16:51:00-05:00,NKTR,neutral
904823.0,"Benzinga's Top Upgrades, Downgrades For November 7, 2017",2017-11-07 09:16:00-05:00,NKTR,positive
904824.0,Cowen & Co. Initiates Coverage On Nektar Therapeutics with Outperform Rating,2017-11-07 08:20:00-05:00,NKTR,neutral
904825.0,Nektar Therapeutics Option Alert: Nov 17 $25 Calls Sweep (7) at the Ask: 510 @ $1.122 vs 880 OI; Ref=$23.91,2017-11-06 09:50:00-05:00,NKTR,positive
904826.0,Watch These 8 Huge Put Purchases In Wednesday Trade,2017-10-11 04:23:00-04:00,NKTR,positive
904827.0,Benzinga's Option Alert Recap From October 10,2017-10-10 16:35:00-04:00,NKTR,positive
904828.0,Nektar Therapeutics Option Alert: Jan 19 $18 Puts Sweep (30) at the Bid: 603 @ $0.65 vs 91 OI; Ref=$23.34,2017-10-10 14:35:00-04:00,NKTR,positive
904829.0,"Benzinga's Top Upgrades, Downgrades For September 27, 2017",2017-09-27 09:18:00-04:00,NKTR,positive
904830.0,"Mizuho Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces $30.00 Price Target",2017-09-27 06:15:00-04:00,NKTR,neutral
904831.0,Nektar Therapeutics Reports Initiation Of PROPEL Study To Evaluate Combo Of NKTR-214 With TECENTRIQ Or KEYTRUDA,2017-09-12 09:05:00-04:00,NKTR,neutral
904832.0,"Nektar Therapeutics Reports Q2 EPS $(0.39) vs $(0.37) Est., Sales $34.589M vs $34.23M Est.",2017-08-08 16:54:00-04:00,NKTR,neutral
904833.0,"Benzinga's Top Upgrades, Downgrades For August 7, 2017",2017-08-07 09:49:00-04:00,NKTR,positive
904834.0,"H.C. Wainwright Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces $31.00 Price Target",2017-08-07 07:06:00-04:00,NKTR,neutral
904835.0,Are Options Traders Betting On A Big Move In Nektar Stock?,2017-07-27 14:31:00-04:00,NKTR,neutral
904836.0,25 Stocks Moving In Monday's Pre-Market Session,2017-07-24 08:22:00-04:00,NKTR,neutral
904837.0,Eli Lilly and Nektar Therapeutics to Partner for Development and Commercialization of NKTR-358,2017-07-24 07:34:00-04:00,NKTR,neutral
904838.0,"Nektar Therapeutics Halted, News Pending",2017-07-24 07:27:00-04:00,NKTR,neutral
904839.0,Nektar Therapeutics' Onzeald Recommended for Approval by the EU Medicines Agency,2017-07-21 07:24:00-04:00,NKTR,positive
904840.0,Nektar Therapeutics Offers Topline Data From Human Abuse Potential Study For NKTR-181: 'shows significantly less abuse potential compared to oxycodone',2017-07-18 08:13:00-04:00,NKTR,negative
904841.0,Nektar Reports Topline Data From Human Abuse Potential Study for NKTR-181 Shows Significantly Less Abuse Potential vs Oxycodone,2017-07-18 08:04:00-04:00,NKTR,negative
904843.0,Nektar Reports New Clinical Data Showing 2 Studies of NKTR-214 at ASCO,2017-06-05 09:03:00-04:00,NKTR,neutral
904844.0,Watch These 7 Huge Call Purchases In Monday Trade,2017-06-05 04:19:00-04:00,NKTR,positive
904845.0,Option Alert: Nektar Therapeutics Jun 23.0 Calls Sweep: 600 @  ASK  $0.35: 768 traded vs 43 OI:  Earnings 8/2 After Close (est)  $20.04 Ref,2017-06-02 12:05:00-04:00,NKTR,positive
904846.0,"Nektar Therapeutics Reports New Research Collaboration with Takeda Pharma for Exploration of Combo Cancer Therapy Approaches with NKTR-214, 5 Takeda Cancer Therapy Compounds",2017-05-22 09:03:00-04:00,NKTR,negative
904847.0,"Nektar Therapeutics Reports Q1 EPS $(0.42) vs $(0.41) Est., Sales $24.72M vs $26.8M Est.",2017-05-09 17:01:00-04:00,NKTR,neutral
904848.0,Watch These 8 Huge Call Purchases In Monday Trade,2017-04-17 04:32:00-04:00,NKTR,positive
904849.0,Benzinga's Option Alert Recap From April 13,2017-04-13 16:49:00-04:00,NKTR,positive
904850.0,Option Alert: Nektar May 15.0 Calls Sweep: 1999 @  ASK  $3.80: 2501 traded vs 5516 OI:  Earnings 5/3 After Close [est]  $18.32 Ref,2017-04-13 13:17:00-04:00,NKTR,positive
904851.0,Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide,2017-03-20 14:34:00-04:00,NKTR,positive
904852.0,Roth Capital Raises Nektar Therapeutics Price Target From $23 To $31 Citing Powerful Efficacy In NKTR-181 Data,2017-03-20 14:11:00-04:00,NKTR,positive
904853.0,12 Biggest Mid-Day Gainers For Monday,2017-03-20 12:38:00-04:00,NKTR,neutral
904854.0,Mid-Day Market Update: Nektar Surges After Positive Results From NKTR-181 Study; Cerulean Pharma Shares Drop,2017-03-20 12:13:00-04:00,NKTR,positive
904855.0,Nektar Hurting Shorts With Positive Results From NKTR-181 Study,2017-03-20 10:52:00-04:00,NKTR,positive
904856.0,Mid-Morning Market Update: Markets Mostly Flat; Washington Companies Proposes To Acquire  Dominion Diamond,2017-03-20 10:03:00-04:00,NKTR,positive
904857.0,22 Stocks Moving In Monday's Pre-Market Session,2017-03-20 08:16:00-04:00,NKTR,neutral
904858.0,Nektar Therapeutics Resumes Trading at 8:00 AM ET,2017-03-20 07:39:00-04:00,NKTR,neutral
904859.0,"NKTR-181 Meets Primary, Secondary Endpoints in Phase 3 SUMMIT-07 Study",2017-03-20 07:30:00-04:00,NKTR,neutral
904860.0,Nektar Therapeutics Halted News Pending,2017-03-20 07:28:00-04:00,NKTR,neutral
904861.0,25 Biggest Mid-Day Gainers For Thursday,2017-03-02 12:39:00-05:00,NKTR,neutral
904862.0,"Nektar Therapeutics Reports Q4 EPS $(0.28) vs. $(0.26), Sales $37.5M vs. $40.8M Est.",2017-03-01 16:11:00-05:00,NKTR,neutral
904863.0,Benzinga's Option Alert Recap From January 23,2017-01-23 17:12:00-05:00,NKTR,positive
904864.0,Option Alert: Nektar Therapeutics Feb 13.0 Calls Sweep: 952 @  ASK  $0.55: 974 traded vs 100 OI:  Earnings 3/1 After Close (est)  $12.12 Ref,2017-01-23 14:44:00-05:00,NKTR,positive
904865.0,Why The Last Week Of 2016 Could Be Big For Biotech Catalysts,2016-12-27 09:02:00-05:00,NKTR,neutral
904866.0,Watch These 7 Huge Put Purchases In Tuesday Trade,2016-12-06 03:02:00-05:00,NKTR,positive
904867.0,Option Alert: NKTR May17 10.0 Puts Sweep: 828 @  ASK  $1.50: 6155 traded vs 2588 OI:  Earnings 3/1 After Close (est)  $12.73 Ref,2016-12-05 10:15:00-05:00,NKTR,positive
904868.0,Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer 2016 Annual Meeting,2016-11-09 14:30:00-05:00,NKTR,negative
904869.0,Benzinga's Top Initiations,2016-11-08 09:22:00-05:00,NKTR,positive
904870.0,"Aegis Capital Initiates Coverage On Nektar Therapeutics - Common Stock at Buy, Announces $21.00",2016-11-08 06:22:00-05:00,NKTR,neutral
904871.0,"Nektar Therapeutics Reports Q3 Loss/Share $0.32 vs Est Loss/Share $0.36, Rev $36.336M vs $32.42M Est",2016-11-03 17:22:00-04:00,NKTR,neutral
904872.0,"Nektar Therapeutics Insider R. Scott Green Direct Acquired 15,000 Common Shares At $13.50/Shr On Oct 24, Now Holds 121,333 Shares - Form4",2016-10-26 06:44:00-04:00,NKTR,positive
904873.0,15 Biggest Mid-Day Losers For Wednesday,2016-10-19 12:36:00-04:00,NKTR,negative
904874.0,16 Stocks Moving In Wednesday's Pre-Market Session,2016-10-19 08:20:00-04:00,NKTR,neutral
904875.0,Nektar Reports Offering of $175M in Common Shares,2016-10-17 16:01:00-04:00,NKTR,positive
904876.0,Brean Likes Nektar Therapeutics' Upcoming Launches; Assumes Coverage At Buy,2016-09-30 08:34:00-04:00,NKTR,positive
904877.0,"Brean Capital Assumes Nektar Therapeutics at Buy, Announces $23.00 PT",2016-09-30 06:19:00-04:00,NKTR,neutral
904878.0,7 Stocks Which Plummeted Three Days On Increasing Volume,2016-09-28 09:36:00-04:00,NKTR,neutral
904879.0,"Bristol-Myers, Nektar Therapeutics Report Oncology Clinical Collaboration to Evaluate Combo of Opdivo, NKTR-214",2016-09-27 06:59:00-04:00,NKTR,neutral
904880.0,"Nektar Therapeutics Reports Q2 Loss -$0.36 vs Est Loss/Share -$0.33, Rev $32.768M vs $30.47M Est",2016-08-03 17:37:00-04:00,NKTR,negative
904881.0,Nektar Therapeutics Reports Preclinical Data For NKTR-214,2016-06-06 14:02:00-04:00,NKTR,neutral
904882.0,"Nektar Therapeutics Names John Nicholson COO, Gil Labrucherie CFO",2016-06-02 16:30:00-04:00,NKTR,neutral
904883.0,Brean Weighs In On Nektar ONZEALD Deal,2016-06-01 19:09:00-04:00,NKTR,neutral
904884.0,Nektar Therapeutics Reports Signing of European Licensing Deal for ONZEALD with Daiichi Sankyo Europe,2016-06-01 08:16:00-04:00,NKTR,neutral
904885.0,"Nektar Reports Q1 EPS $(0.14) Vs Est $(0.23), Sales $58.882M Vs Est $43.78M",2016-05-03 17:53:00-04:00,NKTR,neutral
904886.0,Nektar Therapeutics Presents Pre-Clinical Data Combining NKTR 214 With Checkpoint Blockade,2016-04-18 10:09:00-04:00,NKTR,neutral
904887.0,"Nektar Reports Preclinical Data Presented at AACR, Showed Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition",2016-04-18 08:35:00-04:00,NKTR,positive
904888.0,"Nektar Shares Quiet Following Probes Reporter Tweet: 'Nektar Therapeutics  $NKTR  Confirmed, Undisclosed SEC Investigation.  http://buff.ly/1Sqf7uM'",2016-04-01 12:24:00-04:00,NKTR,positive
904889.0,"Nektar Therapeutics Reports Q4 EPS $(0.40) Vs Est $(0.42), Sales $39.4M Vs Est $28.82M",2016-03-01 16:10:00-05:00,NKTR,neutral
904890.0,Baxalta Announces Submission of Supplemental BLAs to Expand Use of ADYNOVATE to Pediatric Patients and Surgical Settings,2016-02-25 16:16:00-05:00,NKTR,positive
904891.0,UPDATE: Nektar Results for NKTR-214 Show Favorable Safety Profile in Non-Human Primates,2016-02-01 09:11:00-05:00,NKTR,positive
904892.0,"Nektar Therapeutics Offers Preclincial Results for NKTR-214: Shows Durable Anti-Tumor Efficacy, Safety, Immune Mechanism in Multiple Tumor Models",2016-02-01 09:11:00-05:00,NKTR,positive
904893.0,Benzinga's Top Initiations,2016-01-28 09:53:00-05:00,NKTR,positive
904894.0,Janney Capital Initiates Coverage on Nektar Therapeutics at Buy,2016-01-28 08:19:00-05:00,NKTR,neutral
904895.0,Stocks Hitting 52-Week Highs,2015-12-29 10:20:00-05:00,NKTR,neutral
904896.0,"Baxalta's ADYNOVATE Meets Endpoints in Phase 3 Study of Hemophilia A Patients Under 12 Years of Age, Nearly 73% Treated Patients Experienced Zero Joint Bleeds",2015-12-21 08:25:00-05:00,NKTR,neutral
904897.0,"Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine",2015-12-08 09:00:00-05:00,NKTR,neutral
904898.0,Baxalta Show Data On ADYNOVATE For New Indications During ASH Conference Meeting,2015-12-07 10:32:00-05:00,NKTR,neutral
904899.0,Baxalta Presents Additional Data on Newly-Approved ADYNOVATE and Plans for New Indications During 57th American Society of Hematology Annual Meeting,2015-12-07 06:47:00-05:00,NKTR,neutral
904900.0,"Baxalta Announces U.S. Availability of ADYNOVATE, New Treatment for Adult Patients With Hemophilia A With a Simple, Twice-Weekly Dosing Schedule",2015-11-30 06:45:00-05:00,NKTR,neutral
904901.0,"Endologix, Express, Rockwell Automation Lead After-Hours Movers To Close Holiday Week",2015-11-27 15:19:00-05:00,NKTR,positive
904902.0,Baxalta Announces FDA Approval of ADYNOVATE  Treatment for Hemophilia A,2015-11-14 08:08:00-05:00,NKTR,positive
904903.0,"Nektar Therapeutics Reports Q3 EPS $(0.06) vs. Est. $(0.24), Rev. $59.952M vs. Est. $44.3M",2015-11-05 16:54:00-05:00,NKTR,neutral
904904.0,Nektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies,2015-10-07 08:45:00-04:00,NKTR,positive
904905.0,"Nektar Shows Data Demonstrating that NKTR-214, a CD122-Biased Immunostimulatory Cytokine, Induces Durable and Specific Anti-Tumor Immunity As a Single-Agent and When Combined with Checkpoint Inhibitors in Preclinical Models",2015-09-21 09:02:00-04:00,NKTR,negative
904906.0,Nektar Announces Receipt of $40 Million Milestone Payment Resulting from First Commercial Sale of MOVENTIG® (naloxegol) Tablets in Major European Market,2015-09-01 08:31:00-04:00,NKTR,neutral
904907.0,Market Panic Has Created 'Compelling' Opportunities In Biotech,2015-08-25 13:06:00-04:00,NKTR,positive
904908.0,"Roth Capital Believes 'Panic Has Created Some Compelling Opportunities on the Long Side' in Biotech; Highlights bluebird bio, Cempra, MacroGenics, Sarepta, uniQure, Nektar, PTC Therapeutics",2015-08-25 09:13:00-04:00,NKTR,positive
904909.0,"Nektar Therapeutics Reports Inline Q2 Loss $0.40, Sales $22.7M Vs Est $21.49M",2015-08-05 17:26:00-04:00,NKTR,negative
904910.0,Baxalta's BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A,2015-07-16 08:33:00-04:00,NKTR,positive
904911.0,Baxalta's BAX 855 Important Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A,2015-07-16 08:31:00-04:00,NKTR,positive
904912.0,Mid-Afternoon Market Update: Dow Drops Over 150 Points; Nektar Therapeutics Shares Spike Higher,2015-06-24 14:58:00-04:00,NKTR,positive
904913.0,Mid-Day Market Update: Box Surges Following Announcement Of Partnership With IBM On Cloud; Sunedison Semiconductor Shares Fall,2015-06-24 14:34:00-04:00,NKTR,positive
904914.0,Mid-Morning Market Update: Markets Open Lower; Lennar Beats Q2 Estimates,2015-06-24 10:20:00-04:00,NKTR,negative
904915.0,Morning Market Gainers,2015-06-24 09:42:00-04:00,NKTR,neutral
904916.0,Benzinga's Top #PreMarket Gainers,2015-06-24 08:13:00-04:00,NKTR,positive
904917.0,Nektar and MD Anderson Cancer Center Releases Phase 1/2 Clinical Research Collaboration for NKTR-214,2015-06-02 08:01:00-04:00,NKTR,negative
904918.0,"Nektar Therapeutics Reports Q1 GAAP EPS $0.25, Sales $108.8M",2015-04-30 16:49:00-04:00,NKTR,neutral
904919.0,Stocks Hitting 52-Week Lows,2015-04-28 10:57:00-04:00,NKTR,negative
904920.0,UPDATE: Nektar Is Also Entitled To $40M  Upon First Commercial Sale Of MOVANTIK In A Major European Country,2015-04-02 09:39:00-04:00,NKTR,positive
904921.0,Nektar Announces $100M Milestone Payment From AstraZeneca,2015-04-02 09:36:00-04:00,NKTR,neutral
904922.0,MOVANTIK (Naloxegol) Tablets For Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain Launched In The US,2015-03-31 09:11:00-04:00,NKTR,negative
904923.0,Nektar Announces Partner AstraZeneca Reported Co-Commercialization Deal with Daiichi Sankyo for MOVANTIK in US,2015-03-19 08:34:00-04:00,NKTR,neutral
904924.0,Morning Market Losers,2015-03-18 09:55:00-04:00,NKTR,negative
904925.0,Benzinga's Top #PreMarket Losers,2015-03-18 08:14:00-04:00,NKTR,negative
904926.0,"Tuesday's After-Hours Movers: Oracle, Papa Murphy's And More",2015-03-17 20:31:00-04:00,NKTR,neutral
904927.0,PREVIEW: Nektar Therapeutics to Resume Trading at 5:50 PM ET,2015-03-17 17:33:00-04:00,NKTR,neutral
904928.0,Nektar Announces Topline Results for NKTR-102 Trial In Press Release,2015-03-17 16:18:00-04:00,NKTR,neutral
904929.0,"UPDATE: Nektar Says Will Explore Potential Regulatory Pathways in US, Europe",2015-03-17 16:16:00-04:00,NKTR,neutral
904930.0,"Nektar Announces Topline Results for NKTR-102 Trial, Shows Did Not Achieve Statistical Significance",2015-03-17 16:16:00-04:00,NKTR,negative
904931.0,Nektar Shares Halted News Pending,2015-03-17 16:09:00-04:00,NKTR,positive
904932.0,Option Alert: Nektar Therapeutics Mar $12 Call; 110 Contract Trade above Ask @$1.98; Now 13.07,2015-03-03 15:23:00-05:00,NKTR,positive
904933.0,Nektar To Begin Phase 3 SUMMIT-07 Study of NKTR-181,2015-02-25 09:28:00-05:00,NKTR,neutral
904934.0,"Nektar Therapeutics Reports Q4 EPS -$0.35 Vs Est -$0.36, Sales $19.6M Vs Est $17.27M",2015-02-24 16:21:00-05:00,NKTR,neutral
904935.0,5 Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years,2015-02-20 09:36:00-05:00,NKTR,positive
904936.0,Baxter Presents Additional Data from Pivotal Study of BAX 855,2015-02-11 09:03:00-05:00,NKTR,neutral
904937.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2,2015-01-12 11:03:00-05:00,NKTR,neutral
904938.0,What Investors Are Expecting Ahead Of Multiple Nektar Therapeutics Catalysts,2015-01-09 12:53:00-05:00,NKTR,neutral
904939.0,5 Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years,2015-01-09 09:19:00-05:00,NKTR,positive
904940.0,Nektar Offers Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of NKTR-102,2014-12-11 18:03:00-05:00,NKTR,negative
904941.0,Nektar Therapeutics's Partner Baxter Intl. Inc. Submits Application For US FDA Approval Of BAX 855,2014-12-01 09:20:00-05:00,NKTR,positive
904942.0,Nektar Therapeutics Announces The FDA Granted QIDP Designation To Bayer's Amikacin Inhale And Ciprofloxacin Dry Powder For Inhalation,2014-11-24 10:14:00-05:00,NKTR,positive
904943.0,Nektar Presents Preclinical Study Findings for Etirinotecan Pegol,2014-11-20 09:06:00-05:00,NKTR,neutral
904944.0,Nektar Therapeutics Reports Q3 EPS of $0.53 vs $0.39 Est; Revenue of $132.90M vs $123.20M Est,2014-11-06 16:16:00-05:00,NKTR,neutral
904945.0,Nektar Reports Positive Opinion from CHMP on MOVENTIG for Treatment of Adults with Opioid-Induced Constipation,2014-09-26 07:30:00-04:00,NKTR,positive
904946.0,"Nektar Presents Positive Preclinical Data On Oral, Peripherally-Acting Kappa Agonist Molecules At 2014 American Academy Of Pain Management Meeting",2014-09-19 09:01:00-04:00,NKTR,positive
904947.0,"Brean Capital Maintains Buy on Nektar Therapeutics, Raises PT to $20.00",2014-09-16 15:04:00-04:00,NKTR,neutral
904948.0,"UPDATE: Nektar Shares Bouncing, Stock Now Up 1.8%",2014-09-16 13:01:00-04:00,NKTR,positive
904949.0,"Shares of Nektar Resume Trade, Stock Now Down 1.4%",2014-09-16 13:00:00-04:00,NKTR,positive
904950.0,Shares of Nektar Therapeutics to Resume Trade at 1 p.m. EDT,2014-09-16 12:43:00-04:00,NKTR,positive
904951.0,Nektar Therapeutics Confirms FDA Has Approved MOVANTIK Tablets for Treatment of Opioid-Induced Constipation,2014-09-16 12:33:00-04:00,NKTR,positive
904952.0,Nektar Therapeutics Spokesperson Says Company Will Issue PR on FDA Approval for Movantik for Opioid-Induced Constipation; Nasdaq Waiting for that PR to Resume Trade in Shares,2014-09-16 11:49:00-04:00,NKTR,positive
904953.0,UPDATE: FDA Posts Approval of 'Movantik for Opioid-Induced Constipation',2014-09-16 10:20:00-04:00,NKTR,positive
904954.0,FDA Has Issued Approval for Nektar's Movantik for Opioid-Induced Constipation,2014-09-16 10:15:00-04:00,NKTR,positive
904955.0,Nektar Therapeutics Shares Halted News Pending,2014-09-16 10:12:00-04:00,NKTR,positive
904956.0,Nektar Therapeutics Reports Q2 EPS of $(0.26) Which May Not Compare $(0.37) Est; Revenue of $28.50M Which May Not Compare $19.76M Est,2014-07-31 17:14:00-04:00,NKTR,neutral
904957.0,"Ladenburg Thalmann Initiates Coverage on Nektar Therapeutics at Buy, Announces $20.00 PT",2014-06-26 07:45:00-04:00,NKTR,neutral
904958.0,Nektar Shares Now Up Nearly 11% Following Resumption,2014-06-12 16:41:00-04:00,NKTR,positive
904959.0,"Nektar Shares Resume Trade, Now Up 1.6%",2014-06-12 16:35:00-04:00,NKTR,positive
904960.0,Nektar Shares to Resume Trade at 4:35 p.m. EDT,2014-06-12 16:23:00-04:00,NKTR,positive
904961.0,Nektar Announces FDA Panel Has Recommended No CV Trial for PAMORA Class Including Movantik,2014-06-12 16:17:00-04:00,NKTR,negative
904962.0,Sucampo Says FDA Did Not Require Company To Reevaluate Clinical Data Because Action Mechanism For Opiod Constipation is Different,2014-06-12 14:45:00-04:00,NKTR,neutral
904963.0,"Progenics, Nektar Still Halted; FDA Advisory Committee Expected To Conclude Thursday",2014-06-12 09:41:00-04:00,NKTR,neutral
904964.0,Nektar Stock Halted As FDA Will Discuss Receptor Antagonists ~ Bloomberg,2014-06-11 07:07:00-04:00,NKTR,negative
904965.0,"UPDATE: Nektar Therapeutics, Progenics Halted for FDA Advisory Committees",2014-06-11 07:07:00-04:00,NKTR,neutral
904966.0,"Nektar Therapeutics, Progenics Halted: Pending News",2014-06-11 06:59:00-04:00,NKTR,neutral
904967.0,"Top Healthcare Movers For June 9, 2014",2014-06-09 14:27:00-04:00,NKTR,positive
904968.0,Small Pharmaceuticals Rallying Following FDA Report,2014-06-09 12:49:00-04:00,NKTR,neutral
904969.0,"Option Alert Nektar Therapeutics Sept $13 Call; 2,163 Contracts Traded vs 40 OI: Currently $11.36",2014-06-09 10:17:00-04:00,NKTR,positive
904970.0,Nektar Presents Positive Preclinical Data for NKTR-214 at ASCO 2014,2014-06-01 10:15:00-04:00,NKTR,positive
904971.0,Nektar Presents Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin-Refractory High-Grade Glioma at ASCO,2014-05-31 15:14:00-04:00,NKTR,positive
904972.0,Nektra Announces Ivan Gergel CMO,2014-05-19 08:08:00-04:00,NKTR,neutral
904973.0,Nektar Therapeutics Reports Q1 EPS of $(0.37) vs $(0.31) Est; Revenue of $46.20M vs $38.68M Est,2014-05-07 17:31:00-04:00,NKTR,neutral
904974.0,"AstraZeneca, Nektar Therapeutics: FDA Meeting to Review  Mu Opioid Antagonists Is Tentatively Scheduled for June 11-12",2014-03-17 17:04:00-04:00,NKTR,negative
904975.0,"MKM Partners Downgrades Nektar Therapeutics to Neutral, Maintains $13.00 PT",2014-02-27 08:12:00-05:00,NKTR,neutral
904976.0,Nektar Therapeutics Sees FY2014 Sales $190.0M-195.0M,2014-02-26 17:30:00-05:00,NKTR,neutral
904977.0,Nektar Therapeutics Reports Q4 EPS of $(0.41) vs $(0.37) Est; Revenue of $31.10M vs $21.70M Est,2014-02-26 16:18:00-05:00,NKTR,neutral
904978.0,"Option Alert: Nektar Therapeutics Mar/Aug $13 Call Spread; 2,000 Spread Trade; Currently $12.29",2014-02-06 10:22:00-05:00,NKTR,positive
904979.0,Nektar Therapeutics Prices 8.5M Share Offering at $12.75/Share,2014-01-22 22:50:00-05:00,NKTR,positive
904980.0,Nektar Therapeutics Announces Public Offering of 8.5M Shares of Common Stock,2014-01-21 16:14:00-05:00,NKTR,positive
904981.0,Nektar Files Mixed Securities Shelf; Announces Offering of 8.5M Shares,2014-01-21 16:10:00-05:00,NKTR,positive
904982.0,Nektar Presents Positive Data from Phase 1 Study of Etirinotecan Pegol in Combination with 5-Flourouracil/Leucovorin at 2014 Gastrointestinal Cancers Symposium ,2014-01-18 12:34:00-05:00,NKTR,positive
904983.0,"Nektar Announces Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy, Could Submit Filings in 2H'15",2014-01-14 08:18:00-05:00,NKTR,neutral
904984.0,Etirinotecan Pegol Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer ,2014-01-14 08:18:00-05:00,NKTR,negative
904985.0,UPDATE: Piper Jaffray Initiates Coverage on Nektar Therapeutics on Expected Attractive Returns,2013-11-27 10:53:00-05:00,NKTR,positive
904986.0,"Piper Jaffray Initiates Coverage on Nektar Therapeutics at Overweight, Announces $20.00 PT",2013-11-26 16:24:00-05:00,NKTR,negative
904987.0,"Piper Jaffray Initiates Coverage on Nektar Therapeutics at Overweight, Announces $20.00 PT",2013-11-26 16:18:00-05:00,NKTR,negative
904988.0,US Stock Futures Edge Lower Ahead Of Earnings,2013-11-19 07:53:00-05:00,NKTR,negative
904989.0,"Nektar, Astra Zeneca Announce NDA for Naloxegol Accepted by FDA",2013-11-19 07:07:00-05:00,NKTR,positive
904990.0,Market Wrap For November 8: Markets Erase Thursday's Losses; Dow Companies Dominate Headlines,2013-11-08 16:57:00-05:00,NKTR,negative
904991.0,Nektar Therapeutics Lowers FY2013 Sales Guidance from $200.0M-210.0M to $175.0M-185.0M vs $205.60M Est,2013-11-07 17:24:00-05:00,NKTR,negative
904992.0,From Nektar Call: Cutting FY13 Sales Guidance,2013-11-07 17:23:00-05:00,NKTR,negative
904993.0,Nektar Therapeutics Reports Q3 EPS of $(0.14) vs $(0.22) Est; Revenue of $60.90M vs $54.34M Est,2013-11-07 17:12:00-05:00,NKTR,neutral
904994.0,Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day ,2013-10-08 11:15:00-04:00,NKTR,neutral
904995.0,Nektar Reports AstraZeneca Receives EMA Acceptance of Marketing Authorization Application for Naloxegol ,2013-09-30 05:41:00-04:00,NKTR,positive
904996.0,"Market Wrap For Friday, September 27: Dow Ends The Week Negative For First Time In Month",2013-09-27 16:29:00-04:00,NKTR,negative
904997.0,Mid-Afternoon Market Update: Cerner Rallies Major Contract While United Airlines Plummets ,2013-09-27 15:51:00-04:00,NKTR,positive
904998.0,Mid-Day Market Update: Finish Line Gains On Upbeat Results; JC Penney Shares Fall,2013-09-27 12:44:00-04:00,NKTR,positive
904999.0,William Blair Reiterates Outperform on Nektar Therapeutics Following NKTR-181 Phase 2 Trial Miss,2013-09-27 11:14:00-04:00,NKTR,negative
905000.0,UPDATE: Brean Capital Lowers PT on Nektar Therapeutics Following NKTR-181 Phase 2 Trial Miss,2013-09-27 11:14:00-04:00,NKTR,negative
905001.0,Mid-Morning Market Update: Markets Open Lower; BlackBerry Reports Q2 Loss,2013-09-27 10:48:00-04:00,NKTR,negative
905002.0,Benzinga's Top Pre-Market Losers,2013-09-27 08:12:00-04:00,NKTR,negative
905003.0,"Brean Capital Maintains Buy on Nektar Therapeutics, Lowers PT to $14.00",2013-09-27 07:11:00-04:00,NKTR,negative
905004.0,Nektar Shares Resume Trade Down 22%,2013-09-26 16:40:00-04:00,NKTR,positive
905005.0,Shares of Netkar to Resume Trade at 4:40PM EDT,2013-09-26 16:24:00-04:00,NKTR,positive
905006.0,Nektar Says Results from Phase 2 Trial of NKTR-181 Missed Primary Efficacy Endpoint,2013-09-26 16:11:00-04:00,NKTR,negative
905007.0,"Nektar Issues Prelim. Topline Results from Phase 2 for NKTR-181, Says Missed Primary Endpoint",2013-09-26 16:10:00-04:00,NKTR,negative
905008.0,Nektar Shares Halted News Pending,2013-09-26 16:05:00-04:00,NKTR,positive
905009.0,"Form 8-K Filing from Nektar Therapeutics Shows AstraZeneca Filed NDA with FDA, AstraZeneca Will Pay Nektar $70M Milestone on Acceptance of NDA",2013-09-16 16:22:00-04:00,NKTR,positive
905010.0,"Cowen & Company Initiates Coverage on Nektar Therapeutics at Outperform, Announces $17.00 PT",2013-09-12 08:24:00-04:00,NKTR,neutral
905011.0,UPDATE: FDA Will Be Holding an Official Briefing at 12:45PM EDT to Discuss an Undisclosed Topic,2013-09-10 12:07:00-04:00,NKTR,neutral
905012.0,FDA Traders Considering Admin. Updates Labels on Long-Acting Painkillers,2013-09-10 12:04:00-04:00,NKTR,neutral
905013.0,Form 8-K from Nektar Therapeutics Shows AstraZeneca Filed NDS with HC for Naloxegol on Aug. 26th,2013-08-28 17:05:00-04:00,NKTR,neutral
905014.0,"Market Wrap For Monday, August 12: Stocks Close Mixed To Start Week ",2013-08-12 16:42:00-04:00,NKTR,neutral
905015.0,Mid-Afternoon Market Update: Silver Continues Strong Rally as Sarepta Remains Down,2013-08-12 15:33:00-04:00,NKTR,positive
905016.0,Nektar Therapeutics Sees FY2013 Sales $200.0M-210.0M vs $200.80M Est,2013-08-08 17:27:00-04:00,NKTR,neutral
905017.0,Nektar Therapeutics Reports Q2 EPS of $(0.37) vs $(0.44) Est; Revenue of $33.90M vs $26.22M Est,2013-08-08 16:49:00-04:00,NKTR,neutral
905018.0,"Option Alert: Nektar Therapeutics September 12 Call; 7,591 Contracts Traded vs 473 Open Interest; Currently $11.78",2013-08-01 11:04:00-04:00,NKTR,positive
905019.0,"Market Wrap for Wednesday, June 19: Stocks Plunge as Federal Reserve Discusses Pulling Back Stimulus ",2013-06-19 16:26:00-04:00,NKTR,neutral
905020.0,"Mid-Day Market Update: La-Z-Boy Drops On Q4 Results, Nektar Gains",2013-06-19 12:32:00-04:00,NKTR,positive
905021.0,Afternoon Market Gainers,2013-06-19 12:29:00-04:00,NKTR,neutral
905022.0,Nektar Issues Data from Human Abuse Liability Study for NKTR-181,2013-06-19 08:32:00-04:00,NKTR,negative
905023.0,Nektar Announces Positive Preclinical Data for NKTR-214,2013-06-03 09:07:00-04:00,NKTR,positive
905024.0,Nektar Announces Target-Specific Biomarkers Being Evaluated in Phase 3 BEACON Study of Etirinotecan Pegol ,2013-06-01 14:31:00-04:00,NKTR,neutral
905025.0,"Form 8-K Showing Affymax, Lonza Announces Sales Pact to End Supply Deal, Affymax Made $5.975M Payments to Lonza, Nektar",2013-05-31 16:19:00-04:00,NKTR,neutral
905026.0,Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013 ,2013-05-21 09:26:00-04:00,NKTR,neutral
905027.0,Nektar Therapeutics Reports Q1 EPS of $(0.48) vs $(0.42) Est; Revenue of $23.0M vs $26.33M Est,2013-05-09 16:18:00-04:00,NKTR,neutral
905028.0,"Stocks to Watch for April 19, 2013",2013-04-19 08:48:00-04:00,NKTR,neutral
905029.0,"Bayer Initiates Phase III Trial of BAY41-6551T, Delivered by a Pulmonary Drug Delivery System Developed by Nektar Therapeutics",2013-04-16 05:52:00-04:00,NKTR,neutral
905030.0,"UPDATE: Deutsche Bank Reiterates Buy Rating, Lowers PT on Nektar Therapeutics on Q4 Loss",2013-03-01 11:27:00-05:00,NKTR,negative
905031.0,"Deutsche Bank Maintains Buy on Nektar Therapeutics, Lowers PT to $12.00",2013-03-01 07:47:00-05:00,NKTR,negative
905032.0,Nektar Therapeutics Sees FY2013 Sales $200.0M-210.0M vs $175.20M Est,2013-02-28 17:40:00-05:00,NKTR,neutral
905033.0,Nektar Therapeutics Reports Q4 EPS of $(0.46) vs $(0.44) Est; Revenue of $21.10M vs $19.12M Est,2013-02-28 16:16:00-05:00,NKTR,neutral
905034.0,"Lazard Capital Markets Initiated Coverage on Nektar Therapeutics at Buy, Announced $15.00 PT",2013-01-15 10:01:00-05:00,NKTR,neutral
905035.0,Mid-Day Market Update: Markets Slump; Facebook Remains Up on Massive Volume,2012-11-14 14:14:00-05:00,NKTR,neutral
905036.0,"UPDATE: Bank of America Lowers Nektar Therapeutics PO, Maintains Underperform",2012-11-13 09:52:00-05:00,NKTR,negative
905037.0,"Bank of America Maintains Nektar Therapeutics at Underperform, Lowers PT from $7.50 to $7",2012-11-13 08:30:00-05:00,NKTR,negative
905038.0,"Nektar Therapeutics Plunges on FDA Worries, Downgrade",2012-11-12 15:42:00-05:00,NKTR,negative
905039.0,"UPDATE: Jefferies & Company Downgrades Nektar Therapeutics to Hold, Lowers PT",2012-11-12 09:30:00-05:00,NKTR,negative
905040.0,"Jefferies & Company Downgrades Nektar Therapeutics from Buy to Hold, Lowers PT from $10 to $8",2012-11-12 07:28:00-05:00,NKTR,negative
905041.0,A Peek Into The Market Before The Trading Starts,2012-11-12 07:17:00-05:00,NKTR,neutral
905042.0,AstraZeneca Announces Positive Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation ,2012-11-12 06:39:00-05:00,NKTR,positive
905043.0,Nektar To Discuss Positive Phase 3 Clinical Results For Naloxegol ,2012-11-12 06:25:00-05:00,NKTR,positive
905044.0,Nektar Therapeutics Reports Q3 EPS $-0.38 vs $-0.39 Est,2012-11-09 16:00:00-05:00,NKTR,neutral
905045.0,"Option Alert: Nektar Therapeutics December 11 Call; Block Trade: 2,800 Contracts @$1.15, Currently $9.63",2012-10-23 15:30:00-04:00,NKTR,negative
905046.0,"Option Alert: Nektar Therapeutics December 11/14 Call Spread; Block Trade: 10,000 Contracts @$0.92; Currently $10.68",2012-10-16 13:07:00-04:00,NKTR,negative
905047.0,"Deutsche Bank Maintains Nektar Therapeutics at Buy, Raises PT from $11 to $13",2012-10-02 06:33:00-04:00,NKTR,neutral
905048.0,Stocks Hitting 52-Week Highs,2012-09-27 10:08:00-04:00,NKTR,neutral
905049.0,Nektar Therapeutics Says Got Positive Data from Phase 1a Study of NKTR-192,2012-09-18 09:26:00-04:00,NKTR,positive
905050.0,"Jefferies & Company Maintains Nektar Therapeutics at Buy, Raises PT from $9.50 to $10",2012-08-10 06:28:00-04:00,NKTR,neutral
905051.0,"Citigroup Maintains Nektar Therapeutics at Buy, Raises PT from $9 to $11",2012-08-10 06:21:00-04:00,NKTR,neutral
905052.0,Nektar Therapeutics Reports Q2 EPS $-0.30 vs $-0.34 Est; Revenues $23.7M vs $19.90M Est,2012-08-09 16:17:00-04:00,NKTR,neutral
905053.0,Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol,2012-08-07 08:37:00-04:00,NKTR,neutral
905054.0,"Option Alert: Nektar Therapeutics November 11 Call; Block Trade: 2,465 Contracts @$0.60; Currently $9.14",2012-07-24 11:35:00-04:00,NKTR,negative
905055.0,Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181,2012-07-24 08:01:00-04:00,NKTR,neutral
905056.0,Hedge Fund Manager Martin Shkreli Remains Short Nektar Therapeutics,2012-06-20 14:18:00-04:00,NKTR,neutral
905057.0,Nektar Announces that FDA Grants Fast Track Designation to NKTR-181,2012-06-07 08:05:00-04:00,NKTR,positive
905058.0,Top 4 Small-Cap Stocks In The Biotechnology Industry With The Highest Cash,2012-06-04 03:39:00-04:00,NKTR,positive
905059.0,"Option Alert: Nektar Therapeutics Call Volume at 1,283% of Average; Currently $6.87",2012-05-25 13:05:00-04:00,NKTR,positive
905060.0,Nektar Doses First Subjects in Phase 1 Clinical Study Evaluating NKTR-192,2012-04-02 08:31:00-04:00,NKTR,neutral
905061.0,Nektar Reports that Partner Affymax Has Announced FDA Approval of OMONTYS Injection for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis  ,2012-03-28 08:01:00-04:00,NKTR,positive
905062.0,UPDATE: Hearing Nektar Therapeutics to Receive Royalties if MAP Pharmaceuticals Drug is Approved; Chatter is Drug Won't be Approved,2012-03-26 14:36:00-04:00,NKTR,positive
905063.0,Hearing Nektar Therapeutics to Receive Royalties if MAP Pharmaceuticals Drug is Approved,2012-03-26 14:23:00-04:00,NKTR,positive
905064.0,"Morning Social Media Outlook for Thursday Mar 1 (CPRT, NKTR, RIMM, FNSR)",2012-03-01 10:01:00-05:00,NKTR,neutral
905065.0,Nektar Therapeutics Reports Q4 EPS $-0.33 vs $-0.48 Est; Revenues $15.8M vs $12.66M Est,2012-02-29 16:16:00-05:00,NKTR,neutral
905066.0,Nektar Therapeutics Up 7% After Selling Royalty Payment Agreements,2012-02-29 15:13:00-05:00,NKTR,positive
905067.0,"Option Alert: Nektar August 8 Call; Block Trade, 5,000 Contracts",2012-02-29 14:27:00-05:00,NKTR,negative
905068.0,"Option Alert: Nektar May 6 Call; Block Trade, 2,000 Contracts",2012-02-29 09:56:00-05:00,NKTR,negative
905069.0,Nektar Therapeutics Rises 11% on Royalty Deal,2012-02-29 09:03:00-05:00,NKTR,neutral
905070.0,Nektar Therapeutics Resumes Trading,2012-02-29 09:00:00-05:00,NKTR,neutral
905071.0,PREVIEW: Nektar Therapeutics to Resume Trading at 9am,2012-02-29 08:37:00-05:00,NKTR,neutral
905072.0,Nektar Therapeutics Announces Agreement to Sell CIMZIA and MIRCERA Royalties to Royalty Pharma for $124M,2012-02-29 08:31:00-05:00,NKTR,positive
905073.0,"Nektar Therapeutics Halted, News Pending",2012-02-29 08:25:00-05:00,NKTR,neutral
905074.0,Some stocks to watch for Thursdays session,2012-02-01 17:38:00-05:00,NKTR,neutral
905075.0,"UPDATE: Bank of America Downgrades Nektar Therapeutics to Underperform, Maintains $6 PT",2012-01-20 09:02:00-05:00,NKTR,neutral
905076.0,Bank of America Downgrades Nektar Therapeutics to Underperform,2012-01-20 06:58:00-05:00,NKTR,neutral
905077.0,Baxter Initiates Phase I Clinical Trial of Longer-Acting Recombinant FVIII Treatment for Hemophilia A  ,2012-01-05 08:35:00-05:00,NKTR,neutral
905078.0,Notable Call Options Activity on Nektar Therapeutics,2011-12-28 13:08:00-05:00,NKTR,neutral
905079.0,Nektar Announces Positive Clinical Data from Second Phase 1 Clinical Study of NKTR-181,2011-12-13 07:30:00-05:00,NKTR,positive
905080.0,Nektar Therapeutics Initiates Phase 3 BEACON Trial of NKTR-102 in Women with Metastatic Breast Cancer ,2011-12-12 07:30:00-05:00,NKTR,negative
905081.0,Nektar Reports Affymax Announced FDA Advisory Committee Voted in Favor of Benefit/Risk Profile for Peginesatide for Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis  ,2011-12-08 08:23:00-05:00,NKTR,positive
905082.0,Disclosure Insight Maintains Medium Risk Rating on Nektar Therapeutics ,2011-11-29 06:58:00-05:00,NKTR,negative
905083.0,Nektar Therapeutics Hits 52-Week Low of $4.10,2011-11-23 11:48:00-05:00,NKTR,negative
905084.0,Nektar Therapeutics Hits 52-Week Low of $4.16,2011-11-21 09:31:00-05:00,NKTR,negative
905085.0,Nektar Therapeutics hits 52-Week low,2011-11-18 10:10:00-05:00,NKTR,negative
905086.0,NKTR hits 52-Week low,2011-11-16 09:34:00-05:00,NKTR,negative
905087.0,NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer,2011-11-15 18:20:00-05:00,NKTR,negative
905088.0,NKTR hits 52-Week Low,2011-11-15 11:51:00-05:00,NKTR,negative
905089.0,Positive Data for Nektar's New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011,2011-11-14 08:01:00-05:00,NKTR,positive
905090.0,Nektar Therapeutics Reports Q3 EPS $(0.21) vs $(0.37) Est; Revenues $27.10M vs $15.43M Est		,2011-11-03 16:29:00-04:00,NKTR,neutral
905091.0,UPDATE: Deutsche Bank Lowers Price Target on Nektar Therapeutics to $9,2011-11-03 08:15:00-04:00,NKTR,negative
905092.0,J.P. Morgan Maintains Overweight on Nektar Therapeutics,2011-11-03 07:42:00-04:00,NKTR,negative
905093.0,Deutsche Bank Lowers PT on Nektar Therapeutics to $9,2011-11-03 07:31:00-04:00,NKTR,negative
905094.0,"Nektar Presents Positive Data for Novel Opioid Analgesic, NKTR-181, at the 2011 American Academy of Pain Management Annual Meeting ",2011-09-21 09:06:00-04:00,NKTR,positive
905095.0,Too Big To Fail Party  09-15-2011,2011-09-15 19:39:00-04:00,NKTR,negative
905096.0,Notable Call Options Activity in Nektar Therapeutics,2011-09-15 15:52:00-04:00,NKTR,neutral
905097.0,Nektar Therapeutics Presents Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer,2011-09-10 16:15:00-04:00,NKTR,negative
905098.0,Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181,2011-09-08 08:01:00-04:00,NKTR,neutral
905099.0,UPDATE: Deutsche Bank Lowers PT on Nektar Therapeutics to $11,2011-08-08 07:22:00-04:00,NKTR,negative
905101.0,Deutsche Bank Lowers PT on Nektar Therapeutics to $11,2011-08-08 06:22:00-04:00,NKTR,negative
905102.0,Stocks to Watch for Thursday 7/28/2011: Fresh 52 Week Highs and Lows,2011-07-28 02:37:00-04:00,NKTR,positive
905103.0,Stocks to Watch for Wednesday 7/27/2011: Fresh 52 Week Highs and Lows,2011-07-27 04:37:00-04:00,NKTR,positive
905104.0,5 Trade Setups While Waiting For The Market To Do Something,2011-07-20 12:46:00-04:00,NKTR,neutral
905105.0,"AM Movers, Calender For The Week Ahead",2011-07-18 08:29:00-04:00,NKTR,neutral
905106.0,Stocks to Watch for 6/29/11: Fresh 52 Week Highs and Lows,2011-06-29 04:11:00-04:00,NKTR,positive
905107.0,J.P. Morgan Reiterates Overweight on Nektar Therapeutics,2011-06-08 08:07:00-04:00,NKTR,negative
905108.0,Nektar Therapeutics' NKTR-181 Achieved Long-acting Pk Profile With Analgesic Response And Excellent Safety Profile,2011-06-07 09:02:00-04:00,NKTR,positive
905109.0,J.P. Morgan Maintains Overweight Rating On Nektar Therapeutics,2011-06-02 08:22:00-04:00,NKTR,negative
905110.0,"Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer",2011-06-01 12:13:00-04:00,NKTR,positive
905111.0,Hapoalim Cutting Ocverage On Multitude Of Names,2011-06-01 11:48:00-04:00,NKTR,negative
905112.0,"Deutsche Bank Maintains PT, Rating On NKTR After In-Line Results",2011-04-28 08:15:00-04:00,NKTR,neutral
905113.0,"NKTR Revenue And EPS Below Consensus But ""Neither Truly Matter At This Point,"" Says Brean Murray",2011-04-28 08:14:00-04:00,NKTR,negative
905114.0,FDA Grants Orphan Drug Designation For Nektar's Investigational Drug (NKTR),2011-04-21 08:04:00-04:00,NKTR,positive
905115.0,Nektar Therapeutics Receives FDA Orphan Status Approval -Rumor (NKTR),2011-04-20 15:10:00-04:00,NKTR,positive
905116.0,Nektar Therapeutics Receives FDA Orphan Status Approval -Rumor (NKTR),2011-04-20 15:10:00-04:00,NKTR,positive
905117.0,Nektar Initiates Phase 1 Clinical Study Evaluating NKTR-181,2011-03-21 08:33:00-04:00,NKTR,neutral
905118.0,AstraZeneca Initiates Phase III Clinical Programme Evaluating NKTR-118 for Treatment of Opioid-Induced Constipation,2011-03-15 12:07:00-04:00,NKTR,neutral
905119.0,UPDATE: J.P. Morgan Lowers PT on Nektar Therapeutics to $15 (NKTR),2011-03-02 09:37:00-05:00,NKTR,negative
905120.0,Hapoalim Lowers PT on Nektar Therapeutics to $17 (NKTR),2011-03-02 08:28:00-05:00,NKTR,negative
905121.0,Deutsche Bank Lowers Its PT On Nektar Therapeutics To $14 Following Earnings Report,2011-03-02 07:47:00-05:00,NKTR,negative
905122.0,JP Morgan Lowers PT On Nektar Therapeutics To $15,2011-03-02 07:40:00-05:00,NKTR,positive
905123.0,"Company News for January 20, 2011 - Corporate Summary",2011-01-20 10:01:00-05:00,NKTR,neutral
905124.0,"Company News for January 20, 2011 - Corporate Summary",2011-01-20 09:15:00-05:00,NKTR,neutral
905125.0,Nektar Therapeutics Announces Public Offering ,2011-01-18 16:07:00-05:00,NKTR,neutral
905126.0,BROOKFIELD ASST (BAM) - Profit Tracks,2011-01-13 07:01:00-05:00,NKTR,positive
905127.0,BROOKFIELD ASST (BAM) - Profit Tracks,2011-01-13 00:00:00-05:00,NKTR,positive
905128.0,Nektar Therapeutics Falls 8.3% (NKTR),2010-12-13 15:15:00-05:00,NKTR,neutral
905129.0,Deutsche Bank Maintains Buy on Nektar Therapeutics,2010-12-13 09:39:00-05:00,NKTR,neutral
905130.0,Positive Data From Nektar Therapeutics,2010-12-13 08:51:00-05:00,NKTR,positive
905131.0,J.P. Morgan Maintains OW Rating On Nektar Therapeutics ,2010-12-13 08:38:00-05:00,NKTR,neutral
905132.0,"Benzinga's Top Pre-Market NASDAQ Losers (NKTR, PWAV, HBAN, DELL)",2010-12-13 08:26:00-05:00,NKTR,negative
905133.0,Nektar Therapeutics Plunging 9% In Pre-Market,2010-12-13 08:25:00-05:00,NKTR,neutral
905134.0,Hapoalim Securities Raises Target On Nektar Therapeutics (NKTR),2010-11-05 09:43:00-04:00,NKTR,positive
905135.0,"Top 4 Stocks In The Drug Delivery Industry With The Highest Cash (HSP, ELN, NKTR, ALKS)",2010-11-02 04:24:00-04:00,NKTR,positive
905136.0,"Top 4 Stocks In The Drug Delivery Industry With The Highest Cash (ELN, HSP, NKTR, ALKS)",2010-10-14 04:42:00-04:00,NKTR,positive
905137.0,"Top 4 Stocks In The Drug Delivery Industry With The Highest Gross Margin (BVF, ALKS, MTXX, NKTR)",2010-06-25 06:01:00-04:00,NKTR,negative
905138.0,Late Day Short-Covering  06-11-2010,2010-06-11 18:31:00-04:00,NKTR,neutral
905139.0,Market Action Listless - Watching Parade in Chicago?  06-11-2010,2010-06-11 15:11:00-04:00,NKTR,neutral
905140.0,Calls Purchased on Nektar Therapeutics (NKTR),2010-06-11 10:57:00-04:00,NKTR,neutral
905141.0,"Benzinga’s Volume Movers (MDAS, NKTR, TCAP, EQIX)",2010-06-09 13:53:00-04:00,NKTR,neutral
905142.0,Hapoalim Reiterates Buy Rating for Nektar Therapeutics,2010-06-08 08:27:00-04:00,NKTR,neutral
905143.0,"Benzinga's After Hours Gainers (NKTR, KBH, CAB)",2010-05-11 18:44:00-04:00,NKTR,neutral
905144.0,"Benzinga's After Hours Gainers (KEY, VANDA, NKTR)",2010-04-06 18:07:00-04:00,NKTR,neutral
905145.0,William Blair & Co. Outlook For Nektar Therapeutics (NKTR),2010-04-06 14:23:00-04:00,NKTR,neutral
905146.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,NKTR,positive
905147.0,William Blair Maintains Nektar Therapeutics (NKTR) Outperform Rating,2010-03-03 11:20:00-05:00,NKTR,neutral
905148.0,NKTR An Attractive Holding For The Long Term,2010-03-03 09:44:00-05:00,NKTR,positive
905149.0,Wednesday's Hot Stocks: Finding A Rose Among Many Thorns,2010-01-14 08:42:00-05:00,NKTR,neutral
905150.0,"New 52-Week High Stocks (GOOG,TNE,PALM,NKTR,GPS)",2009-09-22 11:27:00-04:00,NKTR,neutral
